• Psychedelic Medicine

Eating Disorders | +40 articles

90



Psychedelics and Anorexia Nervosa*

Claire Foldi, Paul Liknaitzky, Martin Williams, Brian Oldfield

Anorexia Nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the potential for classical psychedelics, including psilocybin, to alleviate symptoms of AN that relate to serotonergic signaling and cognitive inflexibility. Clinical trials using psychedelics in treatment-resistant depression have shown promising outcomes, although these studies are unable to circumvent some methodological biases. The first clinical trial to use psilocybin in patients with AN commenced in 2019, necessitating a better understanding of the neurobiological mechanisms through which psychedelics act.

The neurobiological actions of psilocybin and relevance to AN

Although it is well known that psilocybin, or more specifically its active metabolite, psilocin, acts as an agonist at multiple serotonergic sites, including the 5-HT2A, 5-HT1A, and 5-HT2C receptors, focus has centered on the 5-HT2A receptor binding profile of psilocin due to the finding that specific 5-HT2A antagonists (e.g., ketanserin) block the majority of subjective effects of the drug in human subjects and psilocybin-induced discrimination learning in mice. Psilocybin intake results in dose-dependent occupancy of the 5-HT2A receptor in the human brain, and both plasma psilocin levels and 5-HT2A binding are closely associated with subjective ratings of the intensity of psychedelic experiences.

The other major neurobiological action of psilocybin administration is to decrease activity and functional connectivity within the DMN, a resting state network that is activated during higher-order cognitive tasks, such as considerations of past and future, self-referential cognition as well as personal, social and moral judgments or decision-making. Interestingly, resting state functional connectivity between the executive control network (ECN), a task-positive network primarily involved in cognitive control and emotional processing, and the anterior cingulate cortex is decreased in drug-naïve adolescents developing AN compared to healthy controls. During demanding cognitive tasks, the ECN typically shows increased activation, whereas the DMN shows decreased activation. Accordingly, it may be that psilocybin could act to shift cognitive processing away from an excessive internal focus and toward a more appropriate contextual balance. This style of information processing can more easily adapt to changing environmental needs, perhaps addressing aspects of cognitive inflexibility in patients with AN.

Summary and conclusion

Recent clinical trials have put the spotlight on the therapeutic potential of psychedelics, specifically psilocybin, for a range of psychiatric disorders. The neurobiological and behavioral phenotype of AN, specifically with respect to modified serotonergic signaling and cognitive inflexibility, is well-positioned to be impacted by the putative effects of psilocybin treatment. New treatment strategies for AN are urgently needed, considering that up to 50% of patients with AN never recover, and the risk of death in patients with AN is more than five times higher than in the general population. Converging evidence suggests that psilocybin may be a promising novel treatment for AN, and well-designed trials including those in established animal models are warranted.

*From the article here :
 
Multidisciplinary-Association-for-Psychedelic-Studies-patient-youtube.jpg



MDMA: A Catalyst for ED-PTSD Treatment

by Taschauna A. Richards, MS, RMHCI | Psychedelic Science Review | 28 Sep 2021

Eating disorders (EDs) are among the deadliest psychiatric disorders, altering cognitive function, judgment, emotional stability, and restricting the life activities of sufferers. Early traumatic experiences or adverse events can have a tremendous impact on eating disturbance. Many studies have documented an association between trauma history in those struggling with EDs, with childhood sexual abuse (CSA) being the most well-documented trauma and a significant risk factor. Several studies indicate that sexually assaulted women are more likely to report an ED and poor mental health than women who had not been sexually assaulted. History of trauma is more commonly reported for those diagnosed with bulimia nervosa (BN) in comparison to non-BN patients, and studies also find higher rates of various types of traumas among male and female patients with BN or binge eating disorders compared with the general population, especially with respect to interpersonal traumas. Other types of trauma reported in ED patients include physical and emotional abuse, teasing and bullying, parental separation, and loss of a family member or close friend. The prevalence of traumatic events in ED patients ranges from 37% to 100%, whereas exploring the full diagnosis of posttraumatic stress disorder (PTSD) in ED samples have found a prevalence range from 4% to 52%.

It is more frequently seen for ED-PTSD patients to have experienced multiple traumas. Evidence compiled from national representative samples, community and clinical samples, meta-analyses, and personal patient reports have demonstrated strong links between traumatic experiences and all EDs, particularly those with the clinical features of binge eating and/or purging. In a representative subsample from the National Comorbidity Survey Replication, the reporting rates of any trauma in men and women with bulimia nervosa (BN), anorexia nervosa (AN), and binge-eating disorder (BED) were between 90 and 100%, and most endorsed one or more traumas compared to less than half in the non-ED participants. In another study with a larger database of 36,309 men and women from the National Epidemiologic Survey on Alcohol and Related Conditions, 68% of those with any ED endorsed child maltreatment. In studies that asked about ages of traumas and ED onset, the majority reported traumas occurred prior to or at the same time as the onset of the ED. In the National Women’s Study, 78% of women with BN who reported rape indicated that their first rape predated the onset of binge eating. Additionally, in a community-based prospective longitudinal study of 782 mothers, the occurrence of adverse events during childhood was associated with a significantly higher risk of ED in adulthood. Furthermore, multiple studies confirm that approximately two-thirds of ED patients with PTSD report that their first traumatic event occurred before the onset of their ED with lifetime prevalence rates of PTSD in EDs ranging from 37 to 45% in BN and 21–26% in BED. Lower prevalence rates have been reported in association with AN, however in one series, those with AN with binge and/or purge features had higher lifetime PTSD rates than those with pure AN restricting type.

Current Treatments for Eating Disorders

All aspects of PTSD and trauma-related symptoms such as intrusion, avoidance, hyperarousal, and dissociation have been shown to increase with the number of lifetime traumatic events. Those who have experienced a higher number of traumatic experiences have been linked to ED severity and comorbidities, including food addiction, substance use, and suicide. Trauma histories and PTSD have been reported to predict more complicated prognosis, higher treatment dropout rates, and worse outcomes following treatment. Individuals with ED-PTSD tend to be more impulsive, prone to revictimization, and the subsequent perpetuation of PTSD. Although there are several evidence-based practices for treating both EDs and PTSD individually, there are few findings on integrated treatment approaches for this common comorbidity.

Eating disorders are often connected to traumatic experiences because the behaviors associated with these disorders develop as a coping mechanism, a means of self-protection, a means of escaping the related emotions, or reducing awareness of what they might have experienced. Current treatment is therefore focused on uncovering the emotions associated with the traumatic event(s) through therapeutic approaches such as dialectical behavioral therapy (DBT) and Acceptance and Commitment Therapy (ACT). As eating disorders are often resistant to treatment, third-wave cognitive-behavioral therapies such as DBT and ACT are often effective treatments for eating disorders, which address aspects of the eating disorder pathology beyond the behavior, such as emotion regulation, and experiential acceptance. It is shown that therapy in conjunction with environmental and pragmatic change strategies improve emotion regulation skills, assisting with interpersonal deficits and providing skills for coping with impulsivity to reduce both disordered eating and trauma symptomatology. Process groups have also been proven beneficial in treating trauma and eating disorders as individuals are able to answer the “how” and “why” relating to their experiences, and experiential therapies such as art therapy and animal therapy also allow individuals to express and release emotions in a soothing environment. In order to better understand disordered eating and comorbid trauma, more research is pertinent to enhance conceptualization and better treatment outcomes. MDMA-assisted psychotherapy offers a unique combination of approaches with great healing potential for life-threatening conditions.3

Treating Eating Disorders with MDMA

An important function of EDs can be seen as an attempt to manage difficult emotions as emotion recognition and processing deficits have been considered to play significant roles in symptom expression in the development and continuation of EDs. Functional magnetic resonance imaging (fMRI) studies of patients with EDs have uncovered disturbances in the neural circuits that support emotion processing (amygdala) and self-regulation, i.e., amygdala and dorsolateral prefrontal cortex, (dlPFC). The activation of the amygdala and dlPFC in individuals with EDs are thought to produce enhanced emotional responses in reaction to disorder-relevant stimuli and negative affective states. Such hypervigilance in reaction to possible threatening stimuli may lead to emotional dysregulation and/or over-control, which then furthers primary ED symptoms of restriction, binge eating, and/or purging thus, a greater capacity for emotional regulation in those with ED predicts high treatment success rates.

MDMA operates through the release and reuptake inhibition of serotonin, dopamine, and norepinephrine, which are implicated in both the ill and recovered states EDs, as well as associated comorbidities. MDMA also promotes the release of affiliative neurohormones such as oxytocin (OT), cortisol, arginine vasopressin, and prolactin, which have been reported to be disrupted in EDs. MDMA produces unique psychopharmacological effects such as a decreased feelings of fear, an increased feeling of wellbeing, increased sociability and extroversion, reduced self-criticism, increased compassion for self and others, increased interpersonal trust, and the alert state of consciousness. MDMA has also aided in enhancing acceptance of self and others, increasing tolerance of emotionally upsetting matters, and the ability to address these concerns without disorientation or loss of ego boundaries. Additionally, MDMA alters basic emotional processes, slowing the identification of negative emotions, and increasing responses to positive emotions in others and so, MDMA has theoretical promise as a treatment for ED-related emotional processing, including dysregulation. MDMA reduces amygdala activation and emotional reactivity in EDs, and the anxiolytic and prosocial effects of MDMA can also counteract avoidance and hyperarousal. These factors can introduce an advantageous psychological state to allow the capacity to augment the therapeutic process by providing the opportunity to process emotions fueling the disorder and offer corrective emotional experiences. Current evidence suggests that this function produces some of the most powerful positive changes on PTSD and related symptomatology compared to other evidence-based treatments. These clinical improvements are also shown to be maintained at follow-up assessments 17–74 months after treatment, therefore proving that ongoing administration of MDMA is not required. Improvements have likewise been reported in other important symptoms, including depression, social anxiety, suicidality, substance use, self-esteem, as well as increased self-awareness, trust, and compassion towards others, thereby making it an ideal addition to psychotherapy for PTSD.

Conclusion

Many current eating disorder treatment programs offer a trauma treatment track where therapists specializing in trauma help to uncover emotions associated with traumatic events in order to fully understand and treat the eating disorder at hand.4 MDMA, used in conjunction with psychotherapy to further the processing, healing, and recovery for those combating ED-PTSD, can provide the ability to utilize a psychological state by simultaneously addressing the difficulties of both disorders, allowing these individuals the opportunity to process emotions feeding the disorders, and offer new, restorative emotional experiences. Successful treatment for EDs truly begins when the underlying trauma and the associated emotions are assessed and addressed

 
Last edited:
DEA_Quadruples_Psilocybin_Production_Quota_2021_Psychedelic_Spotlight-710x375.jpg


Positive effects of psychedelics on depression and wellbeing*

M. J. Spriggs, H. Kettner & R. L. Carhart-Harris | 8 Sep 2021

Psychedelic therapy is showing promise for a broad range of mental health conditions, indicative of a transdiagnostic action. While the efficacy of symptom-focused treatments for eating disorders (EDs) is limited, improved mental health and psychological wellbeing are thought to contribute to greater treatment outcomes. This study provides the first quantitative exploration of the psychological effects of psychedelics in those reporting an ED diagnosis.

Methods​

Prospective, online data were collected from individuals planning to take a psychedelic drug. Twenty-eight participants reporting a lifetime ED diagnosis completed measures of depressive symptomology (Quick Inventory of Depressive Symptomology; QIDS-SR16) and psychological wellbeing (Warwick–Edinburgh Mental Wellbeing Scale; WEMWBS) 1–2 weeks before, and 2 weeks after a psychedelic experience. Twenty-seven of these participants also completed a measure of emotional breakthrough [Emotional Breakthrough Inventory (EBI)] in relation to the acute psychedelic experience.

Results​

Bayesian t tests demonstrated overwhelming evidence for improvements in depression and wellbeing scores following the psychedelic experience. Marginal evidence was also found for a correlation between emotional breakthrough and the relevant mental health improvements.

Conclusion​

These findings provide supportive evidence for positive psychological aftereffects of a psychedelic experience that are relevant to the treatment of EDs. It is hoped that this will encourage further research and will bolster initiatives to directly examine the safety and efficacy of psychedelic assisted therapy as a treatment of EDs in future clinical trials.

*From the article here :
 
Last edited:
Anorexia-Nervosa.jpg



Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study*

Meg J. Spriggs, Hannah M. Douglass, Rebecca J. Park, Tim Read, Jennifer L. Danby, Frederico J. C. de Magalhães, Kirsty L. Alderton, Tim M. Williams, Allan Blemings, Adele Lafrance, Dasha E. Nicholls, David Erritzoe, David J. Nutt, Robin L. Carhart-Harris

Anorexia nervosa (AN) is a serious psychiatric condition. The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (1) defines AN by severe nutritional restriction, an intense fear of gaining weight, and a disturbance of one's bodily self-perception. Prevalence rates are highest in females, and onset is most common in adolescence or early adulthood (2, 3). AN is not a Western-bound illness, nor is it constrained to those of a particular age, gender, culture or ethnicity (47).

AN is the most fatal of all psychiatric conditions. Mortality rates are 11.6 times higher than the general population (8). Of these premature deaths, 25% result from suicide, with the reported suicide rate in AN up to 56 times that of the global average (9). Treatment dropout rates in adult patients are also staggeringly high with 20 to 50% of inpatients, and up to 70% of outpatients ending treatment prematurely (3, 1012). Fewer than half of those diagnosed reach remission after specialist treatment (13, 14) and for 20–30%, AN is a life-long condition (15, 16)1. Despite these high mortality and low remission rates, AN research remains severely underfunded with <1% of (the already limited) mental health research funding in the UK allocated to eating disorders, compared with up to 9% for depression (13, 18, 19).

In recent years there has been a surge of interest in the therapeutic use of classic psychedelic drugs; a class of drugs including lysergic acid diethylamide (LSD), psilocybin (the principal psychedelic molecule in magic mushrooms), and dimethyltryptamine (DMT, the principal psychedelic molecule in ayahuasca). There is a growing list of clinical trials highlighting the potential efficacy of psychedelic therapy across conditions (20) including various addictions (2123), obsessive-compulsive disorder (24), depression (2529), and end-of-life anxiety (3033).

The primary receptor-level mechanism of action of classic psychedelics is thought to be via agonism of the serotonin 2A (5-HT2A) receptor. This is understood to induce a spike to wave decoherence that leads to an associated acute “entropic brain state” whereby the spontaneous activity of neural ensembles becomes dysregulated. This 5-HT2A stimulation also induces a hyper-plastic state and a speculated relaxation of the precision weighting of implicit predictive mechanisms. Within the right context, this is thought to promote rapid and deep learning and open a window of opportunity for meaningful psychological transformation (3437). There is also now an increasing understanding that it is the quality rather than the intensity of the acute experience that is predictive of long-term therapeutic outcomes (21, 31, 33, 3840) with growing recognition for the importance of acute emotional-breakthroughs (41, 42).

In AN, aberrant serotonergic activity (43) and reduced synaptic plasticity-related brain-derived neurotrophic factor (BDNF) serum concentrations (44) are thought to contribute to the psychopathology. AN is also characterised by cognitive rigidity (45, 46) and experiential (47) or emotional avoidance (48, 49). Such traits have been demonstrated to change following a meaningful psychedelic experience where the experience of intense emotional states is an important part of the therapeutic process (25, 41, 50, 51). Based on both this neurobiological and psychological evidence, psilocybin assisted-therapy deserves consideration as a potentially novel therapeutic avenue for AN.

There is also preliminary evidence for the efficacy of psychedelics in the treatment of AN. A single case study from 1959 presents a female patient (Miss Henriette B…) for whom two doses of intravenous psilocybin induced “indisputable” therapeutic action (52). Most notable were the patient's acute insights into the perceived root causes of her symptoms, post-acute improvements in mood and well-being, and subsequent weight restoration. Following participation in ceremonial ayahuasca experiences, Lafrance and colleagues reported a reduction or cessation of ED symptoms, improvement in body perception, and increases in self-acceptance in qualitative reports from those with a diagnosis of an ED (53, 54). Finally, in a prospective study, Spriggs et al. (42) demonstrated reductions in depressive symptoms and increases in well-being 2 weeks after a self-initiated psychedelic experience in those reporting a lifetime diagnosis of an ED, with supportive evidence for a role for acute emotional breakthroughs in mediating this change.

These strands of evidence support an early phase clinical trial into the potential of psilocybin-assisted therapy to treat AN. We are not alone is this surmise (55). At the point of writing, there are three trials of therapy with psilocybin (NCT04052568, NCT04505189, NCT04661514) and one study of therapy with 3,4-Methylenedioxy methamphetamine (MDMA; NCT04454684) either currently underway or planned in this population. In summary this represents a novel application for the burgeoning field of psychedelic-assisted therapy, as well as a potential opportunity to address the dire need for new treatment options for AN. Here, we present the protocol for a trial of psilocybin as a treatment for AN that is taking place at the Centre for Psychedelic Research, Imperial College London. First however, we demonstrate how Public Patient Involvement (PPI) was incorporated into the development of the trial, and how this has been crucial in shaping how it will be conducted.

Overview

Here we present the protocol for a pilot study that has been designed to assess the feasibility and preliminary outcomes of treating AN with psilocybin-assisted therapy. Additionally, the study aims to use Magnetic Resonance Imaging (MRI) and Electroencephalography (EEG) to examine the neuronal underpinnings of treatment with psilocybin in this group. Although pilot studies are often perceived as less impactful than larger scale RCTs, their potential influence in shaping the direction of future research should not be understated. It is the overarching goal of any pilot study to provide the optimal information needed to prepare for future studies, and they should therefore be held to the same level of methodological rigour as their larger-scale counterparts (8284). A well-conducted pilot study will not only improve the resource efficiency of future large-scale studies but is also more ethical as it allows for a more data-driven approach to the development of key methods and outcomes (82). The outcomes of this study will sharpen the research focus and evaluate the utility and acceptability of study methods for implementation in a larger-scale (and therefore more costly) study.

Conclusions

Here we have presented a trial protocol for an innovative pilot study assessing psilocybin-assisted therapy as a treatment component for AN. While this trial is one of many exploring psychedelics in mental health treatment, we wish to emphasise how incorporating the voices of those with lived experience has not been beneficial for adapting the psychedelic-therapy approach to this population, but has also been a rewarding experience for researchers and focus group attendees alike. We encourage the integration of PPI initiatives into future psychedelic research, and guidance for doing so has been presented by Close et al. (59).

It is hoped that by presenting our protocol in this format, we will improve the transparency and methodological rigour of the trial which, in turn, will enhance its impact. The insight gained from this pilot study will not only shed light on the potential of psilocybin-assisted therapy in the treatment of AN but will also provide a framework for a more efficient, ethical, and efficacious RCT in the future.

*From the article here :
 
Last edited:
2550071



Could psilocybin curb the global obesity epidemic?*
Trevor Millar tells Psychedelic Spotlight that Psilocybin affects at least the 5h2C receptor, which is responsible for appetite and appetite suppression.

by Greg Gilman | PSYCHEDELIC SPOTLIGHT | 28 Sep 2021

Psychedelic research has yielded no shortage of applications for psilocybin, proven to treat depression, anxiety, PTSD, and chronic migraines. But bioscience company NeonMind firmly believes the psychoactive compound found in “magic mushrooms” is a secret weapon in curbing another big health issue: obesity.

And if you’re skeptical, you’re in good company. Trevor Millar, one of the company’s top psychedelic advisors, tells the Psychedelic Spotlight Podcast that, initially, he couldn’t quite wrap his head around the possibility, either.

“My reaction was probably the same as a lot of people, which is, ‘Really?‘” Millar tells podcast host David Flores in the latest episode. “But as soon as you spend any time thinking about it, you’re like, ‘Yeah.’ If obesity and weight management are issues related to lifestyle, and changes in lifestyle can help people overcome those issues, well then drugs like psilocybin are very good at helping people overcome issues in their life that they want to help overcome. They’re tremendous pattern interrupters.”

So tremendous, in fact, that NeonMind has made obesity its chief focus, developing the first and only novel psilocybin-based drug candidates targeting weight management.

Millar, who previously served as chief psychedelic officer before moving into his current advisory position, explains the company’s strategy as twofold. First up, a clinical trial investigating how a macrodose of psilocybin, along with psychotherapy, can impact individuals struggling with losing weight. Secondly, exploring how microdosing psilocybin can lead to long-term weight loss.

NeonMind expects to have the first patient enrolled in what will be the world’s first psychedelic proof-of-concept study in obese patients in the first half of 2022.

A preclinical trial, involving rats not humans, found promising results. The animals were allowed to eat as much Nutella as they wanted for a 7-day period. The groups that were given either a micro or macrodose of psilocybin added on less weight, compared to the control group that was not administered the psychedelic. According to the company’s website, psilocybin reduced weight gain by 31% and 28% for low and high dose, respectively.

“So, the preclinical data is there,” Millar says. “And then to be maybe somewhat trite, but if anyone out there has taken mushrooms, has anybody really wanted a cheeseburger in the middle of their mushroom journey? It does really affect appetite. It affects at least the 5h2C receptor, which is dedicated towards appetite and appetite suppression.”

The World Health Organization (WHO) has recognized obesity as a global epidemic, costing 2.8 million lives each year. In 2016, more than 1.9 billion adults were deemed to be overweight, with 650 million of those falling in the obese category. “As far as obesity drugs, there’s not many on the market,” Millar says. “They all have some kind of side effects, and none of them are all that effective.”

What makes psychedelics particularly effective in treating various disorders is their power to change behavioral patterns, even after just one dose. So whether it’s a micro or a macrodose of psilocybin, Millar is excited to be exploring the new frontier with NeonMind, and refers to the research of a University of British Columbia professor who has studied obesity for three decades.

“His conclusion, after studying it for 30 years, is what you need in order to actually change a person and help a person is you need to be able to change their mind,” Millar says. “And as Michael Pollan’s book is titled, How to Change Your Mind, that’s exactly what these substances do.”

*From the article here :
 
Last edited:
2-cannabis.jpg



Using cannabinoids to treat obesity

by Gabrielle Giroday | University of Toronto | Medical Xpress | 5 Jan 2022

Though cannabis is often associated with "the munchies" in popular culture, University of Toronto researcher Justin Matheson is asking whether cannabinoids—naturally occurring compounds in the plant—can actually be used to treat obesity.

"On the surface, the research seems a bit paradoxical," says Matheson, who earned a Ph.D. from the Temerty Faculty of Medicine's department of pharmacology and toxicology in 2020 and is now completing a post-doctoral research fellowship in the Translational Addiction Research Laboratory at the Centre for Addiction and Mental Health.

"But what my supervisor [Professor Bernard Le Foll, chair of addiction psychiatry in the Temerty Faculty of Medicine] and others have found is that people who use cannabis regularly actually have lower BMI, lower risk of obesity and a lower of risk of diabetes then people who don't use cannabis."

Matheson is one of the inaugural cohort of the Toronto Cannabis and Cannabinoid Research Consortium (TC3) fellows.

He recently spoke to writer Gabrielle Giroday about his work and the fast-growing field of cannabis- and cannabinoid-related health research.

What interested you in this area of research?

My work is largely focused on substance use and addictions. For my doctorate, I focused on sex and gender and how they impact cannabis use. For example, I published a paper in 2019 looking at how smoking cannabis affected young adults of different sexes.

Before this project, I was already very interested in investigating addiction to cannabis and looking at how cannabinoids can be used to treat substance use disorders.

As for this current research, there are interesting parallels between obesity and overeating, and addiction or substance use disorders. Both involve harmful behavioral patterns that lead to excessive intake of food or psychoactive drugs. It's a new area that deserves further exploration.

Can you explain your approach?

This research will include a randomized controlled trial that will look at if nabilone—a synthetic cannabinoid drug—can reduce body weight in adults with obesity.
We are recruiting a sample of 60 people who have obesity and randomizing them to receive either a high dose of the drug nabilone, a low dose, or a placebo. Participants will be 25 to 45 years old.

Nabilone will be taken as an oral capsule. It's very similar to THC, which is the active component of cannabis, but it's a little structurally different. The study participants will be taking nabilone daily over the course of 12 weeks.

During that period, we'll be monitoring the patients' body weight as well as other measures to see if there are any adverse effects of the nabilone.

In the research, we're not just trying to see if the cannabinoid drug can reduce body weight in adults who are obese, but we're also trying to understand why. We'll do this by using neuroimaging, measuring changes in the gut microbiome, and measuring cannabinoids in the blood and different hormones.

We're also taking measures of participants' brain activity at the baseline, before they enter treatment and at the end of the 12 weeks. Specifically, we're interested in seeing how the neural response to food images changes over the course of treatment.

We've started recruiting participants to take part of the research, and we're hoping to finish the trial in two years.

What do you hope to achieve through this work?

Nabilone is similar to THC. And we know cannabis actually is pro-appetite—in that it increases appetite. In the past, cannabis has been associated with "the munchies" and been used by people with wasting syndromes or who are having problems with appetite. So, on the surface, the research seems a bit paradoxical.

But what my supervisor Le Foll and others have found is that people who use cannabis regularly actually have lower BMI, lower risk of obesity and a lower of risk of diabetes then people who don't use cannabis.

This research will be a first-in-human trial to see if administering nabilone will lead to a lower body weight in adults who are obese, which would replicate animal findings and which would be line with what we're seeing in epidemiological data. We don't know what we'll find yet.

How will you measure the effects of nabilone on each participant?

The endocannabinoid system—which is the body's innate system that underlies the effects of cannabinoids—is a system that is very much involved in all sorts of brain processes such as our perceptions of pleasure and reward. So, we think it's possible our research might find that nabilone reduces participants' responses to food images, which is why we're doing neuroimaging of participants' brains.

Plus, there is also an interesting relationship between cannabinoids and gut bacteria, so we want to measure the gut microbiome to see whether that changes with treatment.

Research has found that people with obesity tend to have higher levels of endocannabinoids, which are the body's own cannabinoid compounds. We believe that taking nabilone, or any cannabinoid drug, over a period of time might disrupt endocannabinoid levels, which could be one way that nabilone leads to a reduction in body weight.

How would you describe the field of cannabis or cannabinoid research these days?

I think cannabis and cannabinoid research has changed, especially after legalization. It's definitely a really growing field and I feel lucky I entered the field when I did in 2015—three years before legalization happened.

I still think there's still a lot of stigma around cannabis use. This affects the participants I work with, who often use cannabis or have a cannabis use disorder. Hopefully, with legalization, this will change.

I think it's a really exciting time to be doing cannabis research, especially because there are a lot of misconceptions. It seems to be a very polarizing topic. You have cannabis advocates who present it as a "cure-all drug," and then you have prohibitionists, who argue it's bad and harming people and should be illegal.

To me, it's somewhere in the middle. There are a lot of misconceptions in the research community and in the general public, which is why the field is so fascinating and why it's where I want to take the rest of my career.

 
Panorama_of_Kings_Parade_in_Cambridge%2C_UK%2C_at_St._Mary%27s.jpg

Cambridge

Anorexia Nervosa: Insights from Psychedelic Medicine*

Claire J. Foldi1(2), Paul Liknaitzky(3), Martin Williams(4,5), Brian J. Oldfield(1,2)

1Department of Physiology, Monash University, Clayton, VIC, Australia
2Monash Biomedicine Discovery Institute, Clayton, VIC, Australia
3Faculty of Health, Deakin University, Burwood, VIC, Australia
4Monash Institute of Pharmaceutical Sciences, Parkville, VIC, Australia
5Psychedelic Research in Science and Medicine Inc., Melbourne, VIC, Australia

Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disease, yet available pharmacological treatments are largely ineffective due, in part, to an inadequate understanding of the neurobiological drivers that underpin the condition. The recent resurgence of research into the clinical applications of psychedelic medicine for a range of mental disorders has highlighted the potential for classical psychedelics, including psilocybin, to alleviate symptoms of AN that relate to serotonergic signaling and cognitive inflexibility. Clinical trials using psychedelics in treatment-resistant depression have shown promising outcomes, although these studies are unable to circumvent some methodological biases. The first clinical trial to use psilocybin in patients with AN commenced in 2019, necessitating a better understanding of the neurobiological mechanisms through which psychedelics act. Animal models are beneficial in this respect, allowing for detailed scrutiny of brain function and behavior and the potential to study pharmacology without the confounds of expectancy and bias that are impossible to control for in patient populations. We argue that studies investigating the neurobiological effects of psychedelics in animal models, including the activity-based anorexia (ABA) rodent model, are particularly important to inform clinical applications, including the subpopulations of patients that may benefit most from psychedelic medicine.​

The Resurgence of Psychedelic Medicine and Therapeutic Potential for AN

Psychedelics were first investigated as therapeutic agents for mental disorders in the 1950s and more than 1000 clinical papers were published on classical psychedelics between 1950 and the mid-1960s. However, political concerns over widespread non-clinical use and governmental interventions associated with an emerging counter culture led to regulatory obstacles and an abrupt end to this promising research. Recently, a resurgence of research into the clinical application of psychedelics has emerged and clinical trials have already highlighted psychedelic medicine as a promising alternative to conventional methods in what is being hailed as a “paradigm shift” for the treatment of psychiatric disorders, including depression, post-traumatic stress and substance use disorders. In addition, the U.S. Food and Drug Administration (FDA) have twice designated psilocybin for treatment-resistant depression as a “breakthrough therapy,” in 2018 and 2019. Combined with specialized psychotherapy, psilocybin has been shown to decrease symptoms of anxiety and depression that accompany life-threatening cancer diagnoses, alleviate symptoms in patients with treatment-resistant depression and improve adherence to abstinence regimes in nicotine-dependent smokers. Moreover, patients with OCD have shown short-term improvements following psilocybin treatment.

Multiple studies investigating the safety and efficacy of psilocybin for the treatment of major depressive disorder have recently commenced across the U.S. and Europe. Importantly, the first Phase 1 study exploring the safety and efficacy of psilocybin in patients with AN was launched in 2019 to examine a range of outcome measures including self-reported anxiety, depression and quality of life as well as changes in body mass index (BMI) and food preference. The findings from this trial will indicate efficacy one way or the other; however, understanding the biological mechanisms that underpin any effects of psilocybin on AN await carefully controlled clinical and animal-based studies.

It should be noted that preliminary support for the efficacy of psychedelics on eating disorder symptoms has been shown in qualitative interviews with patients following the ceremonial consumption of ayahuasca, another serotonergic psychedelic.

An important consideration when interpreting the findings from clinical trials using psychedelics is the inability to circumvent certain methodological biases. Even when niacin or very low dose psychedelics are used as active placebos, most participants and therapists are quickly unblinded to the condition, potentially resulting in expectancy biases. The subjective scales used to measure the efficacy of psilocybin in some studies introduces further bias in the assessment of outcome measures. Irrespective of these limitations, the neurobiological “mechanisms” underlying the efficacy of psychedelics for treatment-resistant depression are beginning to be elucidated in very broad terms through administration of psilocybin in combination with brain imaging techniques. The insights with the most experimental support include alterations in activity and functional connectivity within the Default Mode Network, a group of neural structures that represent resting-state cognition. Functional connectivity between the DMN and other resting state networks is generally shown to increase following administration of psilocybin, and unusual levels of co-activation between DMN and task-positive structures has been found under psilocybin and ayahuasca. The mechanisms underlying the action of psilocybin on functional activity in resting state networks remain poorly understood, particularly the role of the serotonergic system, considering that the major midbrain nucleus in which 5-HT cell bodies is not included in canonical resting state networks. Regardless, mechanistic models have been developed that assert the action of psychedelics as relaxing high-level prior beliefs and liberating bottom-up information flow, and progress is being made to explain the action of psychedelics in the context of complicated neurotransmitter pharmacology, molecular pathways, and plastic changes that contribute to the central actions of these compounds.

FIGURE 1​
fnins-14-00043-g001.jpg

Figure 1. Serotonergic (5-HT) pathways within the brain and the considerable overlap between brain regions implicated in anorexia nervosa (AN), the task-positive executive control network (ECN) and the task-negative default mode network (DMN). These networks are highly interactive and are modulated by activity in the insula (Ins). Changes in functional connectivity within and between these networks are proposed to underlie the impact of psilocybin on cognitive flexibility in AN. dlPFC = dorsolateral prefrontal cortex; vmPFC = ventromedial prefrontal cortex; vStr = ventral striatum; pACC = perigenual anterior cingulate cortex; PCC = posterior cingulate cortex; PPC = posterior parietal cortex.

Anorexia nervosa (AN) has the highest mortality rate of any psychiatric disorder and is characterized by a relentless pursuit of weight loss despite severe emaciation. The majority of patients with AN also engage in excessive physical exercise and other compulsive locomotor strategies to avoid or counteract weight gain. A number of brain imaging studies in AN point to a combination of decreased neural activity in ventral reward regions (ventral and dorsal striatum) and increased neural activity in prefrontal control regions (orbital and dorsolateral prefrontal cortices). This imbalance may underlie the rigid adherence to punishing diet and exercise regimes by patients with AN that is characterized by both excessive behavioral control and diminished cognitive flexibility. Despite the high mortality and the array of pharmacological and psychotherapeutic strategies that have been employed to treat AN, up to 50% of AN patients suffer with chronic, often life-long illness, indicating that therapeutic strategies remain inadequate in treating the core symptoms of the disorder. In this respect, psychedelic medicine in combination with specialized psychotherapy represents a novel therapeutic strategy to treat disorders such as AN where treatment options have historically languished.

The purpose of this review is to highlight the potential suitability of psychedelic medicine for improving long-term treatment outcomes in AN, based on what is known about 5-HT signaling and cognitive function in patients and animal models. Although much of our argument is likely to be applicable to the therapeutic potential of other serotonergic or “classical” psychedelic compounds, including LSD and ayahuasca, we focus here on psilocybin for three reasons: (1) the two FDA designations as a “breakthrough therapy” for treatment-resistant depression; (2) its prevailing use in numerous clinical trials for mental disorders; and therefore (3) the proximity to approval as the first widely used psychedelic in medicine and therapy. Further, we argue that fundamental research in animal models is necessary to reach a comprehensive understanding of the therapeutic effects of psychedelics in psychiatric disease. This is no different to the genesis and clinical acceptance of virtually every other pharmaceutical approach; however, in this instance the use of animal experimentation has the profound advantage of eliminating context and expectation that introduce confounds in the understanding of the neurobiological and pharmacological actions of psychedelic compounds.​

AN, 5-HT2A Signaling and Cognitive Flexibility

The genetic origins of AN have considerable overlap with other psychiatric disorders, most substantially with OCD. These disorders also share phenotypes of cognitive dysfunction that reflect rigid rule-bound behavior and perseverative thinking. AN and OCD have both been associated with a polymorphism in the 5-HT2A promotor, the consequence of which is likely a loss of serotonergic function because patients with AN have reduced 5-HT2A binding compared to healthy controls in the frontal, parietal and occipital cortices. Reduced 5-HT2A binding in cortical regions persists after body weight recovery, indicating that diminished 5-HT2A receptor function is not simply a result of the acute effects of starvation. Several other disturbances in 5-HT signaling have been described as playing a role in the pathophysiology of AN, including alterations in both 5-HT1A receptor and 5-HT transporter binding in cortical and limbic structures and reductions in cerebrospinal fluid concentration of 5-hydroxyindoleacetic acid (5-HIAA), the primary metabolite of 5-HT. These points are consistent with the putative centrality of 5-HT in the genesis of the disorder, which begs the question; how do these neurochemical shifts in the brain manifest as behavioral outcomes? Cognitive inflexibility, linked to 5-HT signaling, is a prominent phenotype in AN and contributes to the persistent drive for weight loss despite the substantial negative consequences of starvation.

Cognitive flexibility is an executive function that includes attentional set-shifting, response inhibition, perseveration and reversal of stimulus-reward associations. Impaired cognitive flexibility has been demonstrated in healthy sisters of AN patients, and persists after body weight recovery, suggesting it has etiological relevance for the development of the disorder. While multiple cortical processes are likely to mediate perseverative tendencies and cognitive inflexibility in AN, impaired set-shifting in AN patients is specifically associated with lower activity of the prefrontal cortex. While it is unclear whether cognitive inflexibility in AN is directly mediated by deficits in 5-HT2A receptor function, the finding that both AN and OCD patients share phenotypic features of behavioral rigidity as well as common genetic etiology involving 5-HT2A transporter function suggests that the two are correlated. In addition, the well-established potential for psychedelics to increase cognitive flexibility is consistent with the intriguing possibility that they may play a therapeutic role in addressing perseverative thinking and behavior in AN.​

The Neurobiological Actions of Psilocybin and Relevance to AN

Although it is well known that psilocybin, or more specifically its active metabolite, psilocin, acts as an agonist at multiple serotonergic sites, including the 5-HT2A, 5-HT1A, and 5-HT2C receptors, focus has centered on the 5-HT2A receptor binding profile of psilocin due to the finding that specific 5-HT2A antagonists (e.g., ketanserin) block the majority of subjective effects of the drug in human subjects and psilocybin-induced discrimination learning in mice. Psilocybin intake results in dose-dependent occupancy of the 5-HT2A receptor in the human brain, and both plasma psilocin levels and 5-HT2A binding are closely associated with subjective ratings of the intensity of psychedelic experiences.

The other major neurobiological action of psilocybin administration is to decrease activity and functional connectivity within the DMN, a resting state network that is activated during higher-order cognitive tasks, such as considerations of past and future, self-referential cognition as well as personal, social and moral judgments or decision-making. Interestingly, resting state functional connectivity between the executive control network (ECN), a task-positive network primarily involved in cognitive control and emotional processing, and the anterior cingulate cortex is decreased in drug-naïve adolescents developing AN compared to healthy controls. During demanding cognitive tasks, the ECN typically shows increased activation, whereas the DMN shows decreased activation. Moreover, the insula, a brain region that plays a critical role in switching between the ECN and DMN in divergent thinking shows disrupted connectivity in patients with AN. Accordingly, it may be that psilocybin could act to shift cognitive processing away from an excessive internal focus and toward a more appropriate contextual balance. This style of information processing can more easily adapt to changing environmental needs, perhaps addressing aspects of cognitive inflexibility in patients with AN.​

Utilizing Animal Models to Interrogate the Neurobiology of AN

One compelling approach to understanding the etiology of AN is to take observations made in humans and rigorously dissect their underpinnings in experimental animal models where brain circuits can be perturbed and anorexic behavior can be interrogated. The most well-accepted animal model of AN, known as activity-based anorexia (ABA), exploits the innate motivation of laboratory rats to run in wheels. When rats with access to running wheels are placed on a restricted feeding schedule, there is a paradoxical increase in running activity despite substantially decreased caloric intake, causing a profound reduction in body weight. It is important to recognize that within this model, food is only limited in terms of time, not quantity. With these same food access constraints and no running wheels, animals quickly learn to increase their food intake to maintain body weight. Similarly, given access to running wheels and free access to food, they maintain their body weight well. It is only the combination of timed availability of food and access to running wheels that initiates the precipitous reduction in body weight that typifies the ABA model. ABA is the only known model where non-human mammals choose self-starvation over homeostatic balance.

There are several behavioral and physiological similarities between ABA in rodents and human AN patients, including a predominance of phenotype in young females, disrupted reward signaling and alterations in hormonal and neuropeptide function. Furthermore, several lines of evidence converge on the roles of reduced 5-HT signaling and cognitive inflexibility in the development of the ABA phenotype, and highlight the translational relevance of this model for examining cognitive deficits in human patients. 5-HT and its metabolites are shown to be maintained at lower levels in animals undergoing ABA compared to controls and deficits in reversal learning have been shown in ABA rats. Other rodent studies implicate the direct impact of 5-HT function on cognitive flexibility, whereby rats lacking the serotonin transporter gene, which results in increased 5-HT availability at the synapse, show improvements in set-shifting and reversal learning paradigms, both measures of behavioral flexibility that are analogs of human cognitive flexibility tasks.​

Effects of Psilocybin in Animal Models

The behavioral effects of psilocybin in animal models appear to be mediated primarily through agonism of the 5-HT2A receptor, because the primary behavioral readout in response to psychedelics in rodents, the head-twitch response (HTR), is absent in mice lacking the 5-HT2AR gene. The other most frequent unconditioned behavioral responses to psychedelics in rodents are disruptions to sensorimotor gating (PPI) and exploratory behavior. Psilocybin also impacts associative learning in animal models by preventing rats from acquiring conditioned avoidance responses and producing more rapid extinction of conditioned fear responses in mice. In addition, psilocybin has been shown to induce dopamine (DA) release in the nucleus accumbens (part of the ventral striatum) and increase extracellular 5-HT levels in the medial prefrontal cortex in rats. This finding is tantalizingly consistent with the proposal that psilocybin could alleviate anorexic symptoms in the ABA model, not only because 5-HT signaling is reduced during ABA, but also because selective activation of DA projections to the nucleus accumbens prevents and rescues the ABA phenotype.

Studies investigating the therapeutic potential of psilocybin in animal models of psychiatric disease have demonstrated significant alleviation of symptoms in mouse models of OCD and PTSD, but did not significantly reduce anxiety phenotypes in wildtype rats or depression-related behavior in a genetic rat model, the Flinders Sensitive Line (FSL). There are several reasons why the significant abatement of depression and anxiety symptoms in human clinical trials was not replicated in these animal studies. It may be that the behavioral test of depression in rodents, the Forced Swim Test (FST), does not fully capture the pathological state of major depressive disorder that is amenable to psilocybin treatment. The FST was originally developed as an antidepressant drug screen and aided the discovery of multiple drugs used successfully in the treatment of clinical depression. However, the behavior of rats and mice in this test is influenced by a number of factors including stress and activity levels, and immobility in this task has been suggested to reflect both adaptive behavior as well as despair. Similarly, although FSL rats are shown to respond to traditional antidepressant medications, they also have markedly lower expression of 5-HT2A receptor mRNA in the frontal cortex, indicating that perhaps the 5-HT2A-mediated effects of psilocybin may have a blunted response in these animals, driven by an inability to bind. This study did not examine the impact of psilocybin on brain function or receptor-specific activity, so whether depressive phenotypes in the FSL model correlate with altered 5-HT2A signaling remains to be resolved.

It is also likely that at least part of the impact of psilocybin on treatment-resistant depression in clinical trials is driven by the higher order subjective characteristics of psychedelic-assisted therapy and the known role of context in the efficacy of psychedelics. Indeed, certain subjective effects are shown to be critical for long-term clinical outcomes across multiple trials. Regardless, it remains the case that ethologically relevant animal models with specific neurobiological and behavioral features that are known to be amenable to the neurobiological impacts of psilocybin will provide unique insight into the therapeutic potential of psychedelics. One example is the ABA model, that displays both cognitive rigidity and disrupted 5-HT function analogous to the human condition. Such studies should test cognitive function in comparable ways to human cognitive test batteries, differentiate effects of single dose administration versus repeated dosing and investigate the impact of non-psychedelic 5-HT2A agonists to challenge the specificity of the effects of psilocybin on behavior and brain function.​

Summary and Conclusion

Recent clinical trials have put the spotlight on the therapeutic potential of psychedelics, specifically psilocybin, for a range of psychiatric disorders. The neurobiological and behavioral phenotype of AN, specifically with respect to modified serotonergic signaling and cognitive inflexibility, is well-positioned to be impacted by the putative effects of psilocybin treatment. New treatment strategies for AN are urgently needed, considering that up to 50% of patients with AN never recover, and the risk of death in patients with AN is more than five times higher than in the general population. Converging evidence suggests that psilocybin may be a promising novel treatment for AN, and well-designed trials including those in established animal models are warranted.

Surprisingly, beyond animal testing for safety and tolerability, the psychedelic research model has thus far largely bypassed the comprehensive screening of drug effects in animal models that usually punctuates the drug discovery pipeline to clinical trials in human patients. This may be based on the premise that psychedelic drugs will not impact animals in the same way as humans because of the uniqueness of the notable phenomenology in humans. Regardless, certain underlying neurobiological effects of psychedelics on cognitive function can be interrogated in animal models with much greater specificity than in human subjects. Animal models of disease also allow determination of the neurobiological effects of psychedelic drugs without the confounds of expectancy and bias that are impossible to control for in patient populations. They have been used successfully over many decades to enable rational pharmacology and the development of more targeted and efficacious medications.

The knowledge gained from animal studies of psychedelic medicines will add substantially to mechanistic accounts of clinical treatments for humans, and may afford improvements and innovations in clinical treatment. The important contribution that animal models can make in progressing the understanding (and possibly development) of psychedelic medicine as a viable therapeutic approach to some mental disorders is in the detailed scrutiny of brain function and behavior they provide. This aligns with a well-worn path whereby detailed mechanistic insights enable rational drug design. However, there is another less tangible benefit that may arise from a better, experimentally based understanding of the actions of psilocybin; reducing stigma associated with the use of psychedelics in a clinical setting. Across a wide range of community attitudes and social bias, it is increasingly recognized that education and understanding are key elements in dismantling stigma. Specifically, a reductionist understanding of the brain circuitry and neurochemistry that mediate the central effects of psychedelic medicines – independent of the confounds of human expectations and context – will help to demystify their clinical effects and hopefully diminish the prejudice associated with their use in the treatment of psychiatric disorders such as AN.

*From the article (including referefences) here :
 
Last edited:
shutterstock_1118458562-2048x1536.jpg



Searching for a better treatment for eating disorders

Cognitive behavioral therapy is proving to work well, but only for some patients. Scientists are seeking new innovations to help people grappling with the pervasive and often-hidden problems of anorexia, bulimia and binge eating.

by Kendall Powell | KNOWABLE | 16 Dec 2021

In 2017, Hennie Thomson checked herself into a hospital for six weeks of in-patient treatment for anorexia nervosa. She was compulsively over-exercising — running, spinning or cross-training three to four hours daily. She ate only one meal each day of the same four foods. And she felt she had hit the bottom of a deep depression.

In the hospital, she would be observed around the clock and her meals would be communal and strictly monitored by health-care staff. She could do no exercise, and would even have an escort to the bathroom.

“It was very overwhelming; I hated losing control and I cried for the first couple of weeks,” recalls Thomson, 27, who works as a portfolio manager in scientific publishing in Oxford, UK. “But I knew I needed it if I was going to ever feel better and recover.”

Thomson’s regimen might appear drastic, but eating disorders, which affect millions of people globally, are some of the most stubborn mental health disorders to treat. Anorexia, in particular, can be deadly. Thomson’s disorder followed a familiar pattern: As is common, it developed when she was an adolescent, and though she had some successes with treatments during high school and university, she suffered a relapse after a major life change — in her case, a move to a new job with unpredictable routines.

She experienced the shame and denial familiar to people with eating disorders, whose biological and psychological urges conspire against them, stopping many from ever seeking treatment at all. Those who do reach out for help have limited and imperfect options: Only psychological interventions are available, and these specialized therapy treatments work only in about half of patients who have access to them.

But in recent years, scientists have made inroads. They know more about which psychological treatments work best, and are hoping to devise new types of therapies by exploring how genetic or neurological causes might underlie some of the disorders.

Meanwhile, an unexpected silver lining to the Covid-19 pandemic was that pivoting to delivering treatments remotely through video calls was largely successful, reports find. This raises the hope that effective telehealth might broaden therapy access to more people, especially those in rural areas.

What is an eating disorder?

While it’s a myth that eating disorders affect only thin, affluent, young white women, it is true that women are diagnosed at numbers much higher than men. Low rates of reporting and treatment make it difficult to know how many people actually are affected, but estimates suggest 13 percent of women and 3 percent of men, representing half a billion women and more than a hundred million men.

The three most common eating disorders are anorexia nervosa, bulimia nervosa and binge-eating disorder. Anorexia is characterized by severely restricted eating and/or over-exercising. It also has the highest mortality rate — up to 20 percent if left untreated — of any psychiatric illness.

Bulimia shows a pattern of binge eating followed by compensating behaviors, such as vomiting or using laxatives. And binge-eating disorder is defined as recurrent episodes of overeating without compensating behaviors. These three disorders share similar psychological patterns — such as a preoccupation with weight and shape — that lead to a loss of control around eating. Although they have different behaviors and physical symptoms, they are treated in therapy in similar ways.

The causes of eating disorders are complex and are usually ascribed to a blend of biological, psychological and cultural influences unique to each individual. As such, general risk factors are hard to nail down. Studies that followed thousands of people before and during the development of an eating disorder while tracking dozens of potential risk factors found that the only consistent, universal risk factor for people with bulimia was a history of dieting. For anorexia, the only clear risk factor was being already thin, with a low body mass index — a measurement of body fat relative to height and weight. (Scientists do not yet know whether this is a sign of sub-clinical anorexia or a factor that predisposes people to developing the disorder.) The studies did not find any consistent risk factors for binge-eating disorder.

More generally, people with anorexia tend to have high levels of anxiety, strong perfectionistic tendencies and commonly have experienced trauma, says anorexia researcher Andrea Phillipou of Swinburne University of Technology in Australia. Therapists report that other common risk factors include having close relatives with an eating disorder and going through stressful major life events, such as going to high school or college, changing jobs or menopause, says Elizabeth Wassenaar, regional medical director for the Eating Recovery Center in Denver.

Only an estimated 25 percent of people with an eating disorder in the US receive treatment. "There are many reasons at play," says Cara Bohon, a psychologist at Stanford University School of Medicine. “There is a lot of denial, guilt, shame and hiding of the problem. And there is still stigma around getting treatment.”

Disorders also often go undiagnosed in men or non-white people due to bias of health-care providers who think these disorders arise only in white women. Access to the kind of specialized therapies that can help some sufferers is limited and expensive. Waits to see therapists can be long in the US and other countries, and eating disorder specific therapy is not available at all in many others. During the pandemic, treatment delays often stretched into many months or, in some places, as long as a year-and-a-half. That’s a huge concern for an illness in which earlier treatment is associated with a greater chance of recovery.

How cognitive behavioral therapy helps

In contrast to other mental health disorders, eating disorders have no drug treatments, only psychological therapies and, for anorexia, medical interventions to re-nourish the body. Since 2003, many therapists have adopted the idea that although these three eating disorders manifest in different ways, the same psychological processes contribute to all three. Therefore, therapies designed to block harmful thought patterns should work for all of them.

Controlled studies have shown cognitive behavioral therapy (CBT) to be the most effective treatment for adults with bulimia and binge-eating disorder. For anorexia, the picture is more complicated and fewer controlled studies have been done, but in those studies, CBT was equally effective as other therapies. Even so, CBT has long-lasting success only for an estimated 30 percent to 60 percent of people, depending on their exact disorder and its severity.

Other forms of psychotherapy, also known as “talk therapy” — such as interpersonal therapy and psychodynamic therapy, which both focus on relationships — can also be effective at treating eating disorders. And for adolescents with anorexia, family-based therapy is the gold standard.

Therapists say that many people struggling with any one of these three disorders find relief in the rigor of CBT, in which therapists literally follow a manual’s protocol. At the same time, CBT is highly collaborative between the therapist and patient, who together come up with “homework assignments” meant to get the person to recognize and interrupt the daily thoughts and behaviors that drive their eating disorder.

“That helps them to see that it’s really them making changes, rather than the therapist prescribing changes,” says psychiatrist Stewart Agras of Stanford University. "For example, the person might be asked to monitor all events around eating — not just what they ate and when, but the location, whether it was with others, and the emotions before, during and after. Another assignment might be to take notice of what activities triggered body-checking in mirrors or negative body image thoughts."

One of the core signatures of eating disorders is a constant assessment of eating, body shape and weight. “The person feels in control when dieting and this is why they continue these behaviors despite the damaging consequences to their health and relationships,” says Riccardo Dalle Grave, director of eating and weight disorders at the Villa Garda Hospital in Garda, Italy.

"Because CBT attacks head-on the thoughts and behaviors common to eating disorders," Agras says, "some people feel they are making progress right away."

Denise Detrick, a psychotherapist who specializes in eating disorders in her private practice in Boulder, Colorado, says she finds it most helpful to use CBT in conjunction with other psychotherapies that are geared toward getting at the root causes of an individual’s eating disorder. She likens CBT to a cast for a treating a broken arm: “CBT helps combat the negative thoughts, and you need that cast, but you’re going to keep breaking your arm over and over again if we don’t understand the cause.”

New insights into the biology of eating disorders

But for all of the evidence behind CBT, it leads to recovery in only about 60 percent of those treated for binge-eating disorder and 40 percent of those treated for bulimia. For anorexia, all treatment methods combined result in recovery for just 20 percent to 30 percent of people treated. That’s clearly not good enough, says Cynthia Bulik, who is looking for more effective treatment possibilities by studying the genetics that underlie eating disorders.

“There is a large genetic component to eating disorders, especially in anorexia and bulimia, where about 50 to 60 percent of the risk of developing the disorder is due to genetic factors,” says Bulik, a clinical psychologist and founding director of the Center of Excellence for Eating Disorders at the University of North Carolina, Chapel Hill. "In binge-eating disorder, that genetic influence is around 45 percent," she says.

In other words, inherited gene variants — likely many hundreds — influence about half of the risk a person has of developing an eating disorder. Not everyone with a particular suite of gene variants will develop one, just as not everyone with a genetic predisposition will develop cancer. The other half of risk comes from environmental, cultural or psychological factors.

There are clear biological and metabolic mechanisms at play. “When most of us are in a negative energy balance — that is, spending more energy than we’re taking in — we get hungry and hangry,” Bulik says. “But people with anorexia find a negative energy balance to be calming. They feel less anxious when they are starving.”

Bulik and others are conducting what are known as genome-wide association studies to catalog the genes that are different in people with eating disorders. The scientists are part of the Eating Disorders Genetic Initiative, which aims to gather genetic and environmental data from 100,000 people with the three common eating disorders from 10 countries in Europe, North America, Asia and Oceania.

The goal is to identify the most common and most influential gene variations, and drill down on what those genes control in the body. That might open the door to discovering medical treatments that could, for example, adjust the affected brain signals in someone with anorexia back to “hungry” when energy runs low.

Phillipou takes another biological approach to eating disorders at her lab at Swinburne University. Her research, on anorexia, explores the connections between specific eye movements and the brain circuits that control them. Interestingly, these eye movements, called square wave jerks, show up much more frequently not only in people in treatment for anorexia and those who have recovered from it, but also in their sisters who have never had an eating disorder.

The area of the brain that controls these eye movements, called the superior colliculus, is involved in integrating information from multiple senses. Phillipou’s group has found that people with anorexia have less connectivity between their superior colliculus and other brain regions. “Potentially, this could mean that people with anorexia are not integrating what they are seeing and feeling about their own bodies properly,” she says.

Her group is testing whether small electric currents delivered through the skull to one of the areas contacted by the superior colliculus, the inferior parietal lobe, can improve the symptoms of anorexia by encouraging more active firing of neurons. (Similar treatments targeting different brain areas are approved in the US for treating depression.)

Another avenue for treating symptoms of anorexia that researchers are exploring is using psilocybin, the psychedelic ingredient found in mushrooms. Psilocybin acts on the same receptors in the brain as the neurotransmitter serotonin, a key molecule for regulating mood and feelings of wellbeing. People with anorexia have less serotonin signaling in certain brain regions compared with people without anorexia.

Dealing with an eating disorder during the pandemic

The pandemic has thrown a dramatic spotlight on just how acute the need for effective treatments has become. “Eating disorders don’t get better in isolation, they get worse,” says Wassenaar of Denver’s Eating Recovery Center.

The loss of control over certain aspects of life that many have felt during the pandemic has been particularly difficult for people with eating disorders, experts say. At Denver Health’s ACUTE Center for Eating Disorders and Severe Malnutrition, a national intensive care unit, the percentage of new, severely ill patients arriving by air ambulance jumped nearly four-fold in April to June 2020 compared with pre-pandemic levels.

In surveys about the pandemic, both people with and without eating disorders reported an uptick in disordered eating, with such behaviors as restricting certain foods, dieting, binging or purging, and increased depression and anxiety. These trends held true for everyone but were stronger for people with eating disorders. And early in the pandemic, more people with eating disorders said that they were worried or very worried about the pandemic’s effects on their mental health versus their physical health (76 percent versus 45 percent).

“That really jumped out at me,” says Bulik, who ran one of the surveys with colleagues from the Netherlands. “All of a sudden, social supports and structure disappeared from our lives.”

The pandemic has also been terrible for adolescents coping with an eating disorder, Wassenaar says. In Michigan, the numbers of adolescents admitted to a children’s hospital for eating disorders was more than double in the year from April 2020 to March 2021 compared with the average of the previous three years. "During adolescence, children need to venture out from the home, connect with friends and gain some sense of control and invincibility," Wassenaar says, "but the pandemic took away many of those activities. Teens are experiencing the world as an unsafe place.”

Lockdowns also forced nearly all therapy sessions to switch to video calls. But this shift may help those who previously were unable to get therapy from a practitioner experienced in treating eating disorders. Even before the pandemic, studies had shown telehealth CBT to be equally effective as face-to-face CBT for a variety of mental illnesses, including bulimia. Many people appreciate the convenience of doing sessions from home. The virtual sessions also cut down on driving time and missed appointments and, therapists hope, could help to expand access to rural areas.

“I see this kind of therapy becoming a norm,” says Agras, who has studied eating disorders for more than 60 years.

Creative coping during Covid

For those like Thomson going through recovery in isolation, creative coping mechanisms become important, experts say. That’s because “getting out of your head and away from the tail-chasing mental thoughts becomes much harder,” says Bulik.

Therapists have had to suggest ways to create structure out of nothing, using sticky-note reminders, doing different activities in different rooms, and not working in or near the kitchen. For example, to help her stick to her weekly meal plans, Thomson packs herself a lunchbox and stores it in the fridge each day even though she is still working from home.

At some points during the pandemic, she also forced herself to pair up with another household, so that she would have to eat dinner with others twice a week. “The friend was a really big foodie who loves to cook, and I had to be okay with that,” Thomson says. Although people with eating disorders often don’t like eating in front of others, experts say that they find the accountability of it and the distracting conversation helpful.

Eric Dorsa, who is also in recovery for anorexia, found ways to build connections and distractions back into their pandemic routines. Dorsa, a 33-year-old eating-disorder and mental health advocate in New York City, rebuilt social connections via FaceTime conversations with friends and runs a virtual support group for LGBTQ+ people in eating-disorder recovery. They also hosted a pandemic-coping miniseries on Facebook Live for the recovery community, called “Quaran-Tea.”

“I had to get a therapist for the first time in six years,” via telehealth, Dorsa says. With the uptick in food fears and news stories of people hoarding food from grocery stores, all of their insecurities around food came flooding back. “I knew I needed help.”

Given that recovery, even with the best therapy, is far from guaranteed and science cannot yet predict who is most at risk for relapse, Bulik and other therapists warn people to keep an eye out for likely triggers — a big move, work travel or schedule changes, loss of a loved one or emotional stress.

Bulik also sees another easy way to help more people with eating disorders: “When physicians take a new patient’s history, there’s no box to check for having a past eating disorder. There should be.”

If you or someone you know is struggling with an eating disorder, the Eating Disorders Review website includes resources, helplines and hotlines.

For help with specific disorders, more information may be found through these US organizations:


National Eating Disorders Association Helpline 1-800-931-2237 (M-Th, 11 am to 9 pm, Eastern US Time; F, 11 am to 5 pm, ET)
National Association of Anorexia Nervosa and Associated Disorders Helpline 630-577-1330 (M-F, 9 am to 5 pm, Central US Time)

10.1146/knowable-121621-1​

Kendall Powell writes about science from her home office (and usually not her kitchen) in Lafayette, Colorado. Follow her @KendallSciWrite.

 
Last edited:
morbid-obesity.jpg



(R)-DOI may revolutionize obesity treatment, study

by Erica Ciko Campbell | Reality Sandwich

Researchers at the Eleusis biotech facility may have finally unlocked the secret to ending the obesity crisis once and for all. The study is still far from conclusive, but the research team’s early findings about a psychedelic substance called (R)-DOI are enough to get the attention of scientists across the country as a potential obesity treatment.

(R)-DOI is short for (R)-2,5-Dimethoxy-4-iodoamphetamine. It hasn’t gained nearly as much traction as some other psychedelics even though it’s been around since the 1980’s. In the research community, it remained relatively unknown until 2015, when researchers found that it may prevent asthma in mice. (R)-DOI’s hallucinogenic effects are similar to LSD, but scientists are far more interested in its mind-blowing potential to treat common obesity-related complications.

New hope for obesity symptoms

In May 2019, the Eleusis research team published a study which suggested that the psychedelic (R)-DOI could change the way we treat the symptoms of obesity.

The main complications of obesity are:
  • Aortal inflammation​
  • Increased cholesterol levels (overall and HDL)​
  • Diabetes​
Currently, the treatment of diabetes and high cholesterol require different drugs. Also, a restricted diet is often necessary. Regardless, patients often find themselves swallowing a whole handful of pills on a daily basis, even though all their problems are caused by one thing: obesity. But, the study suggests that (R)-DOI could be the first-ever drug to tackle all these symptoms at once.

For the study, researchers fattened laboratory mice over the course of four months. Then, the researchers fed saline to one group, while the others received (R)-DOI. As expected, (R)-DOI reduced vascular inflammation in the group that received the (R)-DOI. What researchers did not expect to find was that cholesterol levels also decreased, and glucose tolerance increased, which led to improvement in diabetes. Thus, (R)-DOI could be a true game-changer for the millions of Americans suffering from obesity-related symptoms.

Will (R)-DOI tackle America’s major obesity problem?

According to Healthline, a whopping 36.5% of Americans are obese. Therefore, the results of this study and a possible obesity treatment could have a profound impact on many lives. Theoretically, an obese patient suffering from both diabetes and high cholesterol could take a “micro dose” of (R)-DOI, which would treat all their issues at once. And, the required dose would be so small that patients wouldn’t notice behavioral effects.

In the future, countless patients across the country may be fortunate enough to experience the benefits of (R)-DOI. But clinical trials can often take years, or even decades. Therefore, it will be a while before we know whether the findings are as revolutionary as they appear. MDMA was expedited however to Phase III trials due to their astounding results during Phase II. We hope that (R)-DOI has a similar fate if it proves to be that effective.

The golden age of psychedelics is just beginning

Eleusis is a company that dedicates itself “…to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly referred to as psychedelics.” Lead Researcher Charles Nichols works alongside Shlomi Raz, Chairman and CEO, to explore the endless possibilities of psychedelics through research. Both of them strive to improve countless human lives around the world.

More and more initiatives such as Eleusis are gaining momentum as psychedelics continue to prove just how effective they are. John Hopkins opened the first center for Psychedelic Research. MDMA is currently in Phrase III clinical trials towards FDA approval. We are just beginning to tap into their potential benefits as an obesity treatment, and the range of conditions they may be able to help.

If you’re impressed by the unexpected findings of Eleusis’ research, you aren’t alone. We are living in an era when “psychedelic medicine” is finally being validated and explored. Companies like Eleusis are paving the way towards a better future that addresses medical conditions ethically and efficiently. An amazing discovery like (R)-DOI’s ability to increase insulin tolerance and decrease aortal inflammation is only the beginning.

*From the article here :
 
Last edited:
ReclaimingtheBody6.jpg



Reclaiming ownership of your body with psychedelics
by Jessika Lagarde | Psychedelics Today | 24 Feb 2022

Prolonged negative body image will often lead to depression and anxiety, and unfortunately for many people, can lead to body dysmorphia or an eating disorder. Could psychedelics help reframe one’s relationship with their body?

Psychedelics offer promise for those who struggle with eating disorders – 9% of the world’s population according to the National Association of Anorexia Nervosa and Associated Disorders.

These conditions primarily impact women, and now more of them are coming forward to share how psychedelics are helping them leave a constant cycle of dissatisfaction, body dysmorphia, and the accompanying anxiety, depression, and stress. They explain how the use of psychedelics helped them develop a new relationship with their eating disorders and improve their self-image.

While large-scale studies are (currently) scarce, the anecdotal evidence of these shifts is powerful.

“The first time I sat with a hero’s dose of magic mushrooms, I realized I could put my eating disorder down and never carry it again,” shares Francesca Rose, who is now an eating disorder recovery advocate. “It finally clicked: my eating disorder was not part of me. It wasn’t even mine. It all made sense. I was free from my eating disorder. I no longer needed to control food or my body to feel safe or worthy.” Having her life changed through the use of psychedelics and being on the recovery path for 13 years, this psychedelic-assisted shift is part of what led her to add her current work; supporting other women with eating disorders along their healing journeys.

For many women, talking about their insecurities is still seen as a taboo, weakness, or shameful. Yet finding a supportive space to speak of one’s challenges, plus engaging in embodied experiences – including psychedelic sessions – can offer a gateway to healing. Rose’s work also includes leading embodiment practices via yoga and conscious dance. By helping women speak of their struggles and reconnect to their bodies, she aims to break these stigmas.

Adding in the intentional and safe use of psychedelics can allow women to reconnect with their bodies and cultivate a gentler relationship with themselves. Rose says, “An eating disorder is unconsciously employed as an attempt to feel protected in the world and to even give a sense of meaning and identity. The internal world is fractured and the eating disorder is a way to try to stitch things together, even if it’s an unsustainable method. When we are journeying with psychedelics and engaging in post-journey integration, people can find they rely less on the eating disorder because there is a general sense of ease in the world and more internal wholeness. We can get in touch with our essence, and connect with our inherent worth, belonging, dignity and divinity. Psychedelics can help us embody pride and self-acceptance. We can connect to love, and feel our capacity to give and receive love.”

Understanding Negative Body Image

To have a better understanding of these conditions, we need to first comprehend body image. For most women, it’s not as simple as liking or disliking their own bodies. Body image is complex, and can include a combination of our feelings, beliefs, and perceptions of how our body looks to us and others, the understanding of what it can do, and its estimated size.

Body image issues can start as early as 5 years old. Changes to our physiques kicked off by puberty can deepen our dissatisfaction. Culture also exerts a huge influence on the way we view ourselves. The way society sees gender, the color of skin and hair, and countless other things can also impact the way a person thinks and feels about their physical appearance.

Body dysmorphia is a psychological disorder characterized by an excessive concern for the body, causing the person to overvalue small imperfections or even imagine imperfections. This creates a negative body image and lowers self-esteem. It can drive possible eating disorders and problems in social, professional, and personal lives. Both men and women may experience body dysmorphia and eating disorders, though women are three times more likely to have their lives affected by it.

In the United States, approximately 30 million people suffer from some type of eating disorder. Of these 30 million, 70% do not have the assistance of a specialized professional. As a consequence, anorexia nervosa, one of the most common eating disorders, has a 5.9% mortality rate – one of the highest rates within mental health conditions.

The potential of psychedelics in building a positive body image

Eating disorders are notoriously challenging to treat relative to other mental health disorders. Traditional treatments, such as Cognitive Behavioural Therapy (CBT), have a remission rate of about 45%, a relapse rate of about 30% within one year, and can be hard to follow. Now, some experts and researchers are considering psychedelic therapy as an alternative, and are analyzing the potential benefits of this treatment.


“Eating disorders typically develop as maladaptive coping mechanisms when internal resourcing is overwhelmed by what’s happening in a person’s life,” says Lauren Taus, a California-based therapist who offers ketamine-assisted sessions. Taus and other therapists who contributed their perspectives for this piece say that psychedelic therapy can alleviate the symptoms that are normally associated with these conditions, such as depression and anxiety, in ways that traditional therapy fails to achieve. As Dr. Adele Lafrance points out in this article for EdCatalogue, "psychedelic therapy has the potential to alleviate symptoms that relate to serotonergic signaling and cognitive inflexibility, and the induction of desirable brain states that might accelerate therapeutic processes.”

Taus shared an example of her own work with psychedelics as an alternative treatment that helped her with many of her challenges, including her eating disorder: “My experience with empathogens has invited me to see how much conflict was warring inside of me. I saw all the pain of my personal history, and all that was beyond my control in my family system. Fundamentally, these psychedelics invited me to directly process what was beneath the surface. I accessed great grief, rage, and fear while opening to deep levels of love and compassion for myself and everyone else. I understood my parents and the choices they made, so I could forgive them. I also sourced the willingness, desire, and strength to fight for myself – and my life.”

So what is it about psychedelics specifically that can facilitate profound breakthroughs like Taus’? For starters, they can positively impact the Default Mode Network (DMN), which handles communication between brain regions. This region appears to be hyperactive in some mental health conditions, including depression, anxiety, and OCD. And certain hallmarks of eating disorders, such as the poor cognitive flexibility seen in many anorexia nervosa patients, may also be related to an overactive DMN. Studies such as “Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models” indicate that psychedelics lower the activity in this area, and, by doing so, allow us to create new thought patterns, giving us a fresh perspective on life, the world, and ourselves.

Another way that psychedelic psychotherapy can be effective is by helping a person understand the true source of their feelings of dissatisfaction. A 2013 analysis of why eating disorder therapy fails reveals that a patient’s resistance stems from the disorder’s “ego-syntonic” nature. Ego-syntonic means that the ego’s demands and aspirations drive many of the disorder’s behaviors, feelings, and values. Psychedelic substances can offer a temporary dissolution of the ego, allowing the possibility of transformation, healing, and change of certain behaviors, thought patterns, or addictions.

Taus explains that “Psychedelic assisted psychotherapy supports embodied change where traditional psychotherapy often stays in the realm of cognition and intellect. A person, for example, may come to understand with depth and clarity their patterns in therapy, but still struggle to shift them.” For example, a woman might know that purging is a harmful behavior that leads to feelings of shame. “She may even know exactly why and when it all started, but still she may not be able to stop. Psychoactive substances can create experiential shifts that more efficiently translate into internally-led and sustained behavioral change. The job of the therapist is to provide a safe container for the exploration and a good relational context for a person to make sense of the experience and to anchor in the good that comes from it.”

It’s important to highlight that the use of psychedelic substances on their own does not work as a magic bullet and treatments must be done alongside psychotherapy and/or other healing modalities such as journaling and yoga. A holistic approach seems to be the most effective path to long-term healing for women with eating disorders and body dysmorphia.

The research so far

Ketamine, ayahuasca, MDMA, and psilocybin are the four psychedelics that have been the focus of the majority of the latest research for the potential treatment of eating disorders. Let’s take a look at how each one could help with eating disorders:

Ketamine:

Ketamine is a non-classical psychedelic that can alter consciousness for a short period of time. This synthetic compound’s antidepressant qualities have been researched for treating severe depression, PTSD, and OCD.

Ketamine can be administered through IV, injected, taken orally, or it can be insufflated (blown into a body cavity, such as the nasal passages). The dose is titrated according to weight, with the understanding that everyone metabolizes the medicine differently. Ketamine is known for its dissociative effects, such as feeling like things are moving in slow motion or that you are separated from reality, with objects looking different and other characteristics that can be seen in this study.

“With regards to ketamine, the dissociative experience can translate into more joy in embodied experience. Ketamine-Assisted Psychotherapy (KAP) creates a break from the ordinary mind and a loosening of the belief systems that eating disorders are so rigidly held by. From a scientific perspective, psychedelics interrupt the default mode network, which governs self-image, memories, beliefs, and patterns.” says Taus. “The drug essentially creates an opportunity to reorganize the brain into a system that is more supportive for good living. Ketamine also results in increased neuroplasticity, which creates a golden hour opportunity for potent therapy work with a client 24-48 hours after a KAP experience.”

Ketamine-1536x796.jpeg


A few studies include: Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions, Ketamine and Activity-Based Anorexia, and the ongoing work of Dr. Adele LaFrance with Emotion-Focused Family Therapy.


Ayahuasca:

Ayahuasca is a fermented herbal drink that contains dimethyltryptamine (DMT), one of the most potent psychedelic drugs known for its role in shamanic or religious ceremonies. The brew has been utilized as a sacred ritual by various South American Indigenous tribes for at least 1000 years. Journeyers frequently claim mystical and transcendent visions that lead to self-discovery.

The first ever study of ayahuasca’s potential to help people heal from eating disorders was published in 2017, co-led by Dr. Adele Lafrance and Dr. Kenneth Tupper. The majority of the people in the study said that ayahuasca helped to reduce their eating disorder symptoms and showed them the root cause of the disorder. Regarding the purging effects of the brew, participants found it easy to differentiate between an eating disorder purge, and the purge of an ayahuasca experience.

The ayahuasca experience has the ability to favorably affect behavior, stimulating self-reflection and increased awareness. Studies suggest that drinking it can aid in the treatment of anxiety, addictions, and depression, as well as eating disorders by also shifting body perceptions.

MDMA:

MDMA, another laboratory-created compound, has a physiological effect that alters people’s behavior such as openness. MDMA boosts serotonin levels while also upping oxytocin, dopamine, and other chemical mediators, resulting in feelings of empathy, trust, and compassion. The substance also has an effect on the way people process trauma and emotions for a period of several hours.

In clinical settings, MDMA is taken orally in capsules. The patient first takes a full dose (75-125 mg) and has the option to add a second dose about 2 hours into the session. An MDMA session will typically last between 6 to 8 hours.

MDMA causes an increase in prefrontal cortex activity, which is important for information processing, and a slowing in the amygdala, the part of the brain that is key in processing memories and emotions associated with fear. The key therapeutic benefit of MDMA is its capacity to excite the brain, allowing it to create and store new memories. Patients become more emotionally flexible and capable of exploring challenging memories during psychotherapy sessions, which often leads to long-term changes in how they react to emotional changes.

Psilocybin:

Psilocybin is a substance generated by more than 100 different mushroom species around the world. Psilocybin is said to have the best safety profile of all psychedelic substances. The fungi could be useful in the treatment of eating disorders by targeting the brain’s serotonin imbalance and therapeutically shifting the person away from symptom-focused treatment. This could establish changes in self-worth and self-compassion.

Aside from that, the efficacy of psilocybin therapy in the treatment of OCD shows how it could be useful in the treatment of eating disorders, as obsessive thoughts and compulsive and obsessive actions are also common hallmarks of eating disorders.


Psilocybin-1536x762.jpeg



Reclaiming ownership of your body with psychedelics

Psychedelics can help women see their eating disorder as a coping mechanism and not as part of their identity. Once they embody this insight, they can also slowly start to replace bad habits with healthier and kinder new habits. They can rewrite the inner narrative of lies and self-limiting beliefs about their bodies.

Once more, there is a need to emphasize the importance of integration, relationships, and a holistic approach alongside other therapeutic methods and modalities. Change comes with time, effort, and consistency, especially when deconditioning behaviors that have been a big part of our lives for many years.

When asked about how long it takes for those changes to fully take place, Rose points out that “Eating disorders and addiction are transformational experiences that hold enriching value. Indeed, the word, ‘transformation’ means change or conversion. When thinking about recovery, it is not about stopping or restricting a behavior but rather allowing it to change and transform, taking us along for the ride so that our beliefs, feelings, thoughts, behavior, and action take a new form. Grounded, sustainable change does not happen overnight.”

“For me, recovery is about inner personal and spiritual growth, and incremental daily, positive changes. My experience with eating disorders and addiction has led me to believe that they offer lessons and advantages, transforming me into more of who I truly am: alive, free, appreciative, and connected.”


Although more research is still needed to better understand the safety and efficacy of psychedelic medicines and therapy in the treatment of eating disorders, the promising results we’re seeing show that this is a worthy goal to pursue. Stories such as Rose’s and Taus’ are just two among many other women who have experienced transformational change thanks to these compounds.

“With the support of therapy, community, spirituality, and relationships, I no longer judge my body, or effort to dominate her,” says Taus. “My experiences with plant medicines have supported me in understanding my body as a perfect part of nature, and in much the same way that I don’t complain about the shape of a leaf or a wave, I accept – even appreciate – the parts of me I’ve historically struggled with.”

“The power of psychedelic-assisted therapy is in its experiential quality,”
she says. “When knowing meets feeling and understanding, we can galvanize the courage and strength needed to shapeshift our lives and reconstruct ourselves.”

 
Last edited:
binge-eating-2.jpg


FDA approves psilocybin study for Binge Eating Disorder*

by Greg Gilmanon | Psychedelic Spotlight | 23 Dec 2021​

The pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9 billion market potential for such a treatment.

Tryp Therapeutics is ending the year with some welcome news: The Food and Drug Administration has given the company approval to proceed with its Phase 2a clinical trial evaluating the use of synthetic psilocybin for binge eating disorder.

“We are excited to move forward with our Phase 2a clinical trial in binge eating disorder through our partnership with the University of Florida. Our dialogue with the FDA has been productive and has meaningfully improved the design of this study,” said Chairman and CEO Greg McKee on Thursday.

Using psilocybin to treat eating disorders is one of several exciting avenues for promising psychedelic research outside of depression, anxiety, and PTSD — three mental health issues that tend to dominate the conversation as to how psychedelics can help humanity.

Tryp, a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, first submitted the investigational new drug (IND) application to the FDA back in September. The request to proceed with the Phase 2a clinical trial evaluating the company’s novel proprietary psilocybin formulation, TRP-8802, for binge eating disorder and hypothalamic obesity was placed on hold in October. In November, the FDA requested focusing the study specifically on patients with binge eating disorder, and submitting an IND for a separate Phase 2a study to evaluate the use of synthetic psilocybin for patients with hypothalamic obesity.

The study is to be run with Dr. Jennifer Miller at the University of Florida. TRP-8802 is an oral formulation of synthetic psilocybin and would be evaluated in combination with psychotherapy. Tryp is also researching how synthetic psilocybin can be used to treat fibromyalgia, phantom limb pain, and complex regional pain syndrome (CRPS), in addition to hypothalamic obesity and binge eating disorder. All together, Tryp estimates potential market value of this synthetic psilocybin to be worth $12.5 billion, if proven to be safe and effective. The treatment for binge eating disorder, alone, could be worth $2.9 billion.

The National Eating Disorders Association describes bing eating disorder as “a severe, life-threatening, and treatable eating disorder characterized by recurrent episodes of eating large quantities of food (often very quickly and to the point of discomfort); a feeling of a loss of control during the binge; experiencing shame, distress or guilt afterwards; and not regularly using unhealthy compensatory measures (e.g., purging) to counter the binge eating.”

Out of all types of eating disorders affecting at least 9% of the U.S. population, binge eating is the most common eating disorder in the United States. The behavioral pattern can lead to obesity, which the CDC estimates was prevalent 43% of U.S. adults in 2018, up from 31% in 2000. It’s clearly a big problem that keeps getting bigger — and is a costly problem, too. The estimated annual medical cost of obesity in the United States was $147 billion in 2008. By 2016, a study found the aggregate medical cost due to obesity among U.S. adults was $260.6 billion.

Tryp Therapeutics is not the only psychedelic pharmaceutical company on this mission, though.

NeonMind Biosciences is primarily dedicating its efforts to utilizing psilocybin as a treatment for obesity. The compound is known to activate serotonin receptors which can help a person curb their cravings, reduce their appetite and, as a result, eat less.

Tryp did not release details of how the study will proceed, but NeonMind CEO and President Rob Tessarolo previously outlined their multi-pronged approach in an interview with Psychedelic Spotlight.

First, patients may undergo a high-dose psychedelic session, allowing patients to potentially disengage with maladaptive eating habits, and may facilitate new and more positive behavioral patterns to emerge.

Second, patients may undergo a low-dose “maintenance” approach. Tessarolo highlights that psilocybin activates the 5-HT2C receptor, which is a validated target for weight loss by the FDA; stimulation of these receptors will often lead to patients eating less and feeling fuller. “We think that there’s a potentially low dose approach with psychedelics that may also allow us to target that particular receptor, thereby creating some appetite suppression,” said Tessarolo.

WHAT TO KNOW ABOUT BINGE EATING DISORDER

*From the article here :
https://psychedelicspotlight.com/bi...bin-study-tryp-therapeutics-fda-green-lights/
 
Last edited:


Psychedelics offer new route to recovery from eating disorders

Psilocybin, MDMA, and ketamine can lead to a new sense of self and a release from rigid rules for people with anorexia, bulimia, and binge-eating disorder.

by Marianne Apostolides | NEO.LIFE | 3 Feb 2022

Taking MDMA was pivotal for me as I recovered from bulimia. Unlike the people in clinical trials currently assessing the effectiveness of psychedelic-assisted psychotherapy for eating disorders, I didn’t take the drug in a treatment room. Instead, I was at a rave, a lollipop in my mouth, dancing and running my hands through the buzz-cut hair of a friend’s girlfriend. I was also in a state of revelation, enthralled by what I felt in my body: not disgust or discomfort or revulsion, but utter okay-ness. That sounds like a small thing, but, for someone with an eating disorder, it was pure glory.

That was decades ago. Like many with serious and enduring eating disorders, I’ve cycled from one disorder to the other—anorexia, bulimia, binge-eating disorder, all accompanied by obsessive exercise. The behavior is part of my life, sometimes dominating, often kept in check, but never at rest: it’s always there, threatening to overtake me.

This experience is all too common, and often dangerous. Anorexia is the single most deadly psychiatric disorder, with mortality rates from suicide and cardiovascular complications estimated from 3–10 percent. Relapse rates for bulimia are upwards of 60 percent. And binge eating disorder—defined by out-of-control consumption without the purging that characterizes bulimia—is the most widespread of any eating disorder, affecting an estimated 2.8 million Americans.

Given the extent of the problem, and the recent wave of triumphs for psychedelic-assisted psychotherapy—success in treating PTSD, smoking addiction, end-of-life anxiety, major depressive disorder, social anxiety in autism-spectrum disorder, and more—I became curious: If the drugs alone could induce a profound change of perspective for me as a bulimic woman, how might that insight be transformed into therapeutic benefit with the guidance of therapists, in a therapeutic setting, with a mindset focused on the disorder and on health (which, in a way, is just a different kind of order)? I spoke with leaders in the field to find out.

The visceral understanding that comes with psilocybin​


“We need to reframe the question,” says Meg Spriggs, who’s leading a clinical trial on psilocybin-assisted psychotherapy for anorexia at the Centre for Psychedelic Research, Imperial College London. “It’s not necessarily, ‘How do we treat anorexia,’” she says. Instead, the problem we need to address is, “How do we help people engage in the process of recovery?”

Spriggs’s reframing of the questions is actually quite radical, and consistent with the basic premise of psychedelic-assisted psychotherapy: The drug is a catalyst for treatment, not a treatment in itself. That approach runs counter to the model of antidepressants like SSRIs, which are meant to be taken daily, often for many years. With a psychedelics protocol, the drugs are taken only a few times, and are accompanied by two therapists’ guidance before, during, and after the dose session.

Psychedelics seem optimal for eating disorders because they improve “cognitive flexibility,” the ability to be more responsive to changing circumstances rather than to follow a predetermined pattern of behavior or thought. That’s particularly relevant for anorexia, a disease that’s characterized by the self-imposition of rigid rules to control caloric intake and govern exercise—combined with insurmountable anxiety when those rules are taken away. Anorexics feel compelled to cycle through stuttering thoughts, getting locked into actions determined by that rumination. Psilocybin can “break the pattern” of those thoughts and maladaptive behavior, says Natalie Gukasyan, a psychiatrist at Johns Hopkins University who’s leading a clinical trial testing psilocybin-assisted psychotherapy for anorexia.

“A huge chunk of people receiving psilocybin reported long-term positive behavioral change,” Gukasyan says. That’s significant, she adds, because anorexia is a behavioral disorder. “You behave your way into it, and you’ve got to behave your way out of it.” That shift in behavior requires a tremendous amount of strength, she says, allowing someone to “overcome those very deeply ingrained emotional factors that get in the way of recovery.”

This strength can be increased by the demanding nature of a psilocybin session. “It’s not always easy to go through a psilocybin experience—to surrender to it and go where it takes you, potentially to very difficult places,” Spriggs says. That process, which is analogous to the recovery process from anorexia, can provide a sense of “inner courage and compassion,” helping the person remain with the recovery process.

Despite the solid rationale for testing psilocybin for anorexia, the early results from the Johns Hopkins study were puzzling. A few participants reported they felt little effect from the drug: no hallucinations, no dissolution of the ego, no sense of interconnectedness between the self and the world (the famed sense of “oneness”). Some asked whether they’d received a placebo.

The researchers aren’t certain why this is the case, although several plausible hypotheses have been put forward. Perhaps the serotonin receptor density in the brain is too low—either due to the effects of starvation or to factors inherent in anorexia itself—or perhaps the body can’t metabolize psilocybin efficiently, converting it into its usable form, psilocin. Either way, the researchers revised their protocol, allowing for up to four psilocybin sessions, spread over a 12-month period, with higher maximum doses. They’re also considering whether to admit people into the trial who are in partial remission from anorexia—those with a higher stabilized weight and less constrained eating, who are nonetheless terrified of being drawn back into the behavior. “That might be the perfect time to help people really solidify their progress,” Gukasyan says.

As the researchers learn more and adjust their treatment protocol, they’re seeing positive results, with data to be published later this year. Still, Gukasyan says, “It is very different from other studies I’ve been involved in,” with benefits taking longer to develop.

“It’s a really common misconception that this treatment is a magic bullet—you step in, you step out, it’s all fixed,” Spriggs says. “But it’s not like that.” Unlike other disorders like depression and PTSD, where psychedelics have been shown to provide immediate relief, the treatment for anorexia can make people feel worse. That’s because progress often induces anxiety as the protective mechanism of the disorder is threatened. “That’s a huge part of what keeps people from getting better,” Gukasyan says: the ambivalence of giving up a disorder that’s made them feel safe and in control.

That ambivalence plays out in the conflict between knowing you have to eat but being afraid to navigate the day without the disorder’s strict rules. It isn’t logical. The behavior can’t be explained in rational terms, and efforts to provide rational reasons for its development seem incapable of changing the behavior.

I can’t count how many times I’ve been told, often under people’s breath, that my behavior is “bizarre.” This is not unknown to me. But the very bizarreness of the behavior—combined with the heedless drive to deny the body’s most basic need—lends itself to the surreal nature of a psilocybin experience. During the duration of a trip, a person doesn’t feel trapped in the cage of logic; she can slip into a different kind of understanding, where the dynamics underlying the disorder are made visceral and vivid. In my experience, those insights make more sense than any rational, word-based explanation.

All these benefits—acute insights combined with cognitive flexibility, compassion, and courage—contribute to a participant’s motivation to continue recovery. For both studies, motivation for change is one of the primary measurable outcomes. This goes back to Spriggs’ initial reframing of the question: Will psilocybin give people the fortitude to continue engaging with the recovery process—not giving up on themselves, or the goal of someday feeling free from the disorder?

“I remain cautiously optimistic,” Gukasyan says.

MDMA and the possibility of joy​


Another psychedelic under evaluation for eating disorders is MDMA, the synthetic chemical prevalent in ecstasy, a recreational drug once associated with raves. Like psilocybin, MDMA increases neural plasticity, operating on the 5-HT2A receptors to induce the growth of dendrites, the branching part of the neuron that connects to other neurons throughout the brain. Despite binding to the same receptor as psilocybin, the drug produces a completely different experience.

MDMA is known as an “empathogen” because it creates a feeling of compassion—for yourself, your situation, as well as other people, which fosters social bonding and trust. These emotions seem to blossom because MDMA simultaneously reduces fear, allowing people to tolerate feelings that otherwise would’ve overwhelmed them, making them either numb or distraught.

“With MDMA, the fears people typically have around connecting with others in a vulnerable way—a more intimate way—are decreased,” says Adele Lafrance, a clinical psychologist running a trial for anorexia and binge-eating disorder, sponsored by MAPS. By facilitating a feeling of connection, MDMA can create a strong “therapeutic alliance” between participants and therapists, building a level of trust to help a person feel protected while engaging with intense emotions, memories, and thoughts. This is particularly advantageous for treating people with eating disorders, Lafrance says, since they often feel mistrustful in interpersonal relationships, uncertain whether the other person can fulfill—or even acknowledge—their emotional needs.

The sense of trust that flows to the therapists also gets directed inward, Lafrance says. “People start to trust their own internal processes, ranging from bodily sensations—including hunger cues—all the way to the experience of emotion,” including anger and shame. “When you put all that together, you have a beautiful opportunity.”

But that opportunity can also be treacherous. Given the level of openness during a dose session, a participant might feel overly exposed in the days afterward, as if the connection weren’t rooted in anything real. That’s why the preparatory therapy sessions are vital, says Michael Mithoefer, senior medical director for medical affairs, training and supervision at MAPS and the lead author of the training manual for therapists. Those prep sessions, held in the days prior to dosing, ground the therapeutic process in a relationship that’s not dependent on the drug’s effects. The sessions also familiarize the participant with the process that will unfold during dosing—which, in itself, creates a potential pitfall.

“People get really attached to getting better, having a breakthrough,” Mithoefer says. They therefore try to stay with their initial intention rather than following the emotions, recollections, or images that appear during the dose session. “The route to your intention may not be recognizable at the time,” Mithoefer says, “but you may realize it later. We see this so often, if you can let go and not get ahead of the medicine or your inner healing intelligence.”

That phrase, inner healing intelligence, is ubiquitous in the psychedelics community, even though its definition seems to elude many people. Whenever I sought an explanation, it was presented as either self-evident or ineffable, one of those beyond-the-bounds-of-language psychedelic things. Then Mithoefer explained it to me. He used an analogy from his days in emergency medicine, before he became a psychiatrist. He describes the process of helping patients who came to the ER with wounds. He could clean the wounds, get the gravel out, treat an infection—“but that wasn’t doing any healing,” he says. “That was just removing obstacles, creating favorable conditions to allow the healing process—which was innate—to go forward.” The inner healing intelligence, then, is the mind’s “complex and elegant organization” that drives toward wellness, if the obstacles to healing are removed and favorable conditions created.

The notion that MDMA elicits what’s already within us, there and waiting to emerge, can become a promise, like a secret we keep in ourselves. That’s what I felt on that night so many years ago, when I first tried MDMA. The fact that MDMA induces self-compassion can become a truism, but it will have depths of meaning for people with eating disorders because we understand the opposite of self-compassion: the relentless sense of repulsion toward their bodies and behavior. By giving me the ability to feel joyful in my body, MDMA changed the horizon of what was imaginable, and therefore what’s now possible. It must be possible, the drug seems to tell us, because you’ve already felt it: That joy is already yours.

Ketamine and the potential for reordering​


As psilocybin and MDMA proceed toward FDA approval through clinical trials, ketamine is already there: An intranasal derivative of the drug was approved for treatment-resistant depression in 2019. Until now, though, the research on ketamine for eating disorders has been limited to case studies, most of which describe the effects of the drug on its own, without accompanying psychotherapy. This is now changing. Johanna Keeler, a PhD candidate at King’s College, London, is at the forefront of a new wave of scholarship in the field. With her research on the neurobiology of anorexia—specifically, how the brain changes through the duration of the illness—Keeler sees a good fit for ketamine, whose properties could potentially counteract some of the changes caused by starvation.

But this focus on neurobiology doesn’t discount the experiential component, Keeler says, noting that the drug can “expand the mind,” allowing therapeutic insight and better integration of those insights into daily life.

Ketamine, which is primarily used as an anaesthetic, is often said to be “dissociative,” meaning a person feels disconnected from parts of their body: a hand has its own animus, not attached to the mind that sees it. Although some in the field label the dissociative effects of ketamine as “adverse,” Keeler thinks they could be important for achieving a therapeutic benefit.

In interviewing people who’d taken ketamine for alcohol addiction, Keeler found that people “had profound hallucinations and vivid memories, helping them make sense of past traumas and past events” which in turn led to “drastic changes in their life for their well-being,” including abstinence from alcohol for some. Keeler is currently developing a randomized-controlled trial to test whether these effects are translatable to anorexia.

In some ways, ketamine is the inverse of MDMA: It doesn’t show us what we’d want, but shows that what we’ve got isn’t intractable or even solidly real. Our reality is changeable, and that very changeability is a source of hope. A person’s reality—for me, the reality that I must follow strict rules to control my eating and exercise, and thereby stabilize my world—is not the only way to organize the world’s dynamics and how they interact with me. Those types of insights arise not only because of ketamine’s dissociative effects, in which the relations among objects decohere. It’s also the quickness with which those relations come back to coherence—a speed far faster than psilocybin—that allow a reshaping of what’s possible.

The body’s fundamental appetites​


All of these treatments will likely be available to people with anorexia, bulimia, and binge-eating disorders in the next 18 months, experts predict. That seems impossibly soon, since these trials are still in their early stages. But the most likely scenario is that people with eating disorders will benefit from other ongoing trials examining psychedelic-assisted psychotherapy for PTSD.

Given the advanced stage of those clinical trials, psilocybin and MDMA will likely be approved by the FDA for PTSD in 2023. Ketamine is already available for treatment-resistant depression. Because many people with eating disorders also have PTSD or depression, they would be eligible for treatment. For those who aren’t, they could still get the treatment if the drugs are prescribed for “off-label use,” meaning they’re given for conditions beyond the ones listed by the FDA. This is a common practice, with nearly one-third of antidepressant prescriptions currently off-label.

That’s why the data from these studies will be especially crucial for therapists and patients trying to determine whether these treatments are worth the expense and emotional effort. It’s also why bulimia needs to be studied: If the drugs are effective for anorexia and binge-eating disorder, they could also be effective for bulimia, given the underlying similarities of these conditions. But safety needs to be established regarding the physical effects of purging.

Despite these caveats, I, like Natalie Gukasyan, have become cautiously optimistic. That caution veers toward unbridled optimism when the treatments are reframed, as Meg Spriggs suggests—particularly if we clearly say we’re engaging not just with the “process of recovery,” but also with the process of being alive to our bodies, desires, emotions, and relationships, despite the presence of the disorder.

Interestingly, and somewhat disconcertingly, no one I spoke to mentioned appetite—not for sex, or food, or love. From my perspective, that’s central to all eating disorders: the need to control desire. We can talk about rumination, cognitive inflexibility, inability to process emotions. But what is felt, in the body, is the brutality of denying the body’s fundamental appetites.

With that in mind, I wonder whether our discussion around eating disorders is too theorized, too removed from the basic, primal nature of hunger, feasting, and eating. Psychedelics, too, usher us into the primal. This link is not made in scientific discourse, but that doesn’t discount its validity—at least not for people who will walk into that treatment room, with all their hurt and want and hope. I plan to be among them.

Marianne Apostolides is an award-winning author of seven books. She’s currently working on a book about new treatments for eating disorders and what they reveal about the brain, mind, and self. @Apostolides_M

 
DoubleBlind-psychedelics-eating-disorders-SECONDARY.jpg



Psilocybin effective in reducing weight gain, study*

by James Hallifax | Psychedelic Spotlight | 24 Mar 2022

NeonMind finds that its proprietary psilocybin has the ability to target visceral fat, effectively reducing weight gain in obese subjects.

Psilocybin, the hallucinogenic compound in magic mushrooms, has long been thought to be beneficial in treating mental health conditions when combined with therapy. Most famously, many are using the entheogen as a medicine against depression. But research into the compound’s healing ability is not limited there, and there is study into whether the drug can treat PTSD, Alcohol Use Disorder, Generalized Anxiety Disorder and more.

Now, a new front has opened in the psychedelic war against mental health conditions: eating disorders and obesity.

On Wednesday, NeonMind Biosciences released data from a preclinical animal study, demonstrating “the efficacy of psilocybin in reducing weight gain in obese subjects.” Previously, the company had completed a similar study in healthy animal subjects, which also showed the psychedelic reduced weight gain.

Importantly, NeonMind found that psilocybin, or more specifically the company’s version of psilocybin, had the ability to target visceral fat. This is essential since, according to NeonMind, “Increased visceral fat is linked to poorer cardiometabolic health and reduction in this type of fat is important in weight loss and better overall health outcomes.”

In their recent study testing obese animals, NeonMind had several additional findings:​
  1. There was statistical significance for both absolute and relative weight gain compared to the control group;​
  2. Efficacy was seen within days of administration;​
  3. There was reduced food consumption compared to the control group; and​
  4. There were no negative safety signals.​
In other words, in animal subjects at least, psilocybin appeared to be a safe and effective medicine to reduce weight gain. Though, of course, we will have to wait to see the full data released before coming to any final conclusions. NeonMind says a manuscript “has been submitted to a leading industry peer-reviewed journal” and is currently under review for publication.

Now, to be clear, animal trials are the very first step. After this positive data, similar trials must be designed for humans. NeonMind says that the data from this trial will help them progress two versions of psilocybin through the development pipeline, NEO-001 and NEO-002. Eventually, one or both of these compounds should make it to Phase 1 clinical trials.

Looking elsewhere, other companies and institutions are also working with psilocybin or other psychedelics to treat eating disorders. For example, Compass Pathways (Nasdaq: CMPS), through an investigator initiated study, is set to attempt treating Anorexia Nervosa in a Phase 2 trial, using their patented Comp-360 psilocybin.

Likewise, Tryp Therapeutics has begun recruitment for their Phase 2 trial, attempting to treat Binge Eating Disorder with their version of psilocybin, TRP-8802. According to their interim CEO, Jim Gilligan, “The key objective of this clinical trial is to confirm that the neuroplasticity attributes of psilocybin will help create healthy neural connections that address the unhealthy eating behaviors of patients with binge eating disorders.”

And, as I wrote last week for Psychedelic Spotlight, the non-profit MAPS is attempting to treat various eating disorders with MDMA. The institution recently completed a study which looked at the decrease in eating disorder symptoms in PTSD patients who were treated with MDMA therapy. And while that study had positive results, it was by no means conclusive. MAPS plans on running an open-label Phase 2 study this year, attempting to treat eating disorders with MDMA-assisted therapy.

Hopefully these trials yield positive results, as the need for treatments for eating disorders is high. As I wrote last week, eating disorders are the second deadliest mental illness, after opioid addiction.The problem is huge, with 9% of the American population expected to battle with one at some point in their life. Tragically, 26% of Americans with eating disorders make an attempt on their own life, and each year 10,200 succeed. That’s one death every 52 minutes.

If psilocybin and other psychedelics can be effective medicines to battle these psychological illnesses, there may be hope for the millions of people suffering world-wide.

*From the article here :
 
Last edited:
Adele-LaFrance.jpeg



Healing Eating Disorders with Psychedelics

by Jill Ettinger | Psychedelic Spotlight | 7 Dec 2020

Adele Lafrance, PhD, approaches therapy with an open mind. The internationally recognized clinical psychologist, research scientist, and author, is now a leader in the nascent practice of psychedelic medicine, specifically in the use of treating eating disorders.

“I was working in the field of eating disorders for a number of years and though many patients and their families reported positive outcomes, so many continued to struggle,” she recalled.

She lost two patients within a short period of time, one by suicide, and the other to complications from anorexia. “I was gutted, feeling so helpless,” she said.

That’s when she found Dr. Gabor Mate’s documentary: “The Jungle Prescription.” Like most people, she’d not heard of ayahuasca, which is rich in the substance, DMT (N, N-dimethyltryptamine), the most powerful psychedelic on the planet.

Something clicked for LaFrance.

“At the same time, I was undergoing in-vitro fertilization and had already had a failed cycle. I was gutted about that, too. The combination of professional and personal reasons to explore the potential of psychedelics led me to travelling abroad to learn about these medicines.” It was a turning point.

Ayahuasca and Eating Disorders

Then, LaFrance met women with eating disorders using ayahuasca to treat their conditions.

“A few years ago, I interviewed a number of women who participated in conventional eating disorder treatment programs and who’d had the opportunity to participate in ceremonial ayahuasca use,” she tells Psychedelic Spotlight.

LaFrance noticed the women all reported a deeper healing with ayahuasca than other treatments; it was more “efficient” she says. And LaFrance said the women all conveyed that it seemed to lead to “a more embodied experience of healing.”

For example, she says, that “rather than knowing they were worthy of love, they felt worthy of love, and they could describe — even hold the memory of the felt sense in their body long after the experience.”

Research is beginning to validate anecdotal reports. Studies are linking a wide range of psychedelics from DMT to MDMA, psilocybin, LSD, ibogaine, and ketamine, to positive mental health outcomes. LaFrance works with ayahuasca, MDMA, psilocybin and ketamine.

“The field is so new that it is important to learn about each of these substances as they show great promise in the facilitation of healing and growth,” LaFrance says. She believes that they can “awaken” certain innate healing “intelligence” that can promote a mental state more receptive to psychotherapy.

Different doses, processes, and uses of these common psychedelics show potential in treating alcoholism and opioid addiction, as well as eating disorders, anxiety, PTSD, and treatment-resistant depression.

‘All substances have a function’

“I believe that all substances have a function, when used consciously, including SSRIs,” says LaFrance. But upwards of 30 percent of all people diagnosed with depression will not have positive outcomes with SSRIs and other prescription anti-depressants. It’s a number motivating the booming psychedelics industry. More than 20 companies are now publicly traded, working on everything from processes and substance research to delivery mechanisms, treatment facilities, and training therapists to administer and work with patients using the substances.

“Substances should be used in conjunctive with supportive therapy,” LaFrance says. “We heal in relationships no matter the drug we use to facilitate the process and I feel this point is worthy of underlining over and again. In fact, in each of the studies I’ve designed, not only is the relationship between the therapist and the client of great importance, we also involve a family member or close other to widen the circle of care.”

LaFrance says the dialogue around psychedelic treatment still needs expanding. She says therapists don’t need to have had a personal experience with any of the substances, but they do need to be committed to the important task of working with someone under the influence. They need to cultivate trust and respect in a space that is often incredibly intense.

She’s now applying her experience to a number of programs across different psychedelic substance. LaFrance is working with MAPS, as the Strategy Lead and Clinical Investigator for a study it’s funding on MDMA-assisted psychotherapy for eating disorders. She’s serving as the Clinical Supervisor on the Imperial College study for psilocybin and anorexia nervosa. And she is the co-developer of Emotion-Focused Ketamine-assisted Psychotherapy and Emotion-Focused Family Therapy.

As the industry grows and more therapists come to understand the potential in psychedelics, LaFrance is hopeful that it will expand the toolkit for treating eating disorders. “My hope is that as a field, we will work towards coordinating our efforts to bring psychedelic medicines to standard healthcare in a way that is integrated,” she says.

“There is so much research yet to do, but it is so very promising for those struggling to benefit from conventional approaches to psychopharmacology and psychotherapy.”

*From the article here :
 
Last edited:
talking-therapy-ptsd.jpg


MDMA assisted therapy significantly reduces eating disorder symptoms

by Kevin Dinneen | LEAFIE | 21 Mar 2022

Researchers have published a study that shows MDMA assisted therapy (MDMA-AT) produces positive results for patients living with eating disorders and Post Traumatic Stress Disorder (PTSD).

It is estimated that globally 8.4% of women and 2.2% of men live with an eating disorder, in the UK the total figure is estimated to be 1.4 million.

According to the charity Beat, eating disorders are serious mental illnesses affecting people of all ages, genders, ethnicities and backgrounds. People with eating disorders use disordered eating behaviour as a way to cope with difficult situations or feelings. This behaviour can include limiting the amount of food eaten, eating very large quantities of food at once, getting rid of food eaten through unhealthy means (e.g. making themselves sick, misusing laxatives, fasting, or excessive exercise), or a combination of these behaviours.

The rate of eating disorders in people who have PTSD increases significantly, patients suffering from PTSD often suffer from eating disorders, and vice versa. The two are considered to be interrelated psychiatric disorders and together are referred to as ED-PTSD. There are many factors that increase the likelihood of a patient living with ED-PTSD, they include; being female, having a personal and or familiar history of psychiatric disorders and having a history of childhood trauma.

Previous studies researching the efficacy of MDMA-AT at treating PTSD have produced promising results, however, little research has been done to explore its role in the treatment of ED-PTSD of which there is currently no proven treatments available.

In this study, 90 participants were assessed using the Eating Attitudes Test 26 (EAT-26). The EAT-26 is a standardised tool used within medicine and psychiatry to assess the risk of a patient having an eating disorder, the higher the score the higher the likelihood of someone being at risk of having an eating disorder.

The researchers hypothesised that a substantial number of the participants with PTSD would demonstrate higher EAT-26 scores, even if they were not actively self-purging or clinically underweight. They also predicted that participants who receive the MDMA-AT would have significantly reduced EAT-26 scores compared to those who receive the placebo, it was expected that females would have lower scores after the MDMA-AT.

Patients selected to take part in the double-blind, placebo-controlled pivotal study had all been previously diagnosed with severe PTSD and were tested for ED risk using the EAT-26 tool. They each took part in three experimental 8-hour sessions, spaced four weeks apart.

Half of the cohort received 80-180mg of MDMA per experimental session which was paired with talking therapy, and the other half received an inactive placebo coupled with talking therapy. Before the experimental sessions, the participants were asked to undergo a 10 hour fast to reduce the risk of nausea and vomiting.

During the experimental sessions, therapists talked with individual participants and helped them work through painful memories of traumatic events, with the intention of ‘reaching an emotional resolution’. After each experimental session, the participants took part in three 90 minute follow-up sessions aimed at addressing any difficult situations, and also to help them integrate any lessons learned into their daily lives.

A total of 82 of the original 90 participants completed the study. The results showed a significant difference between EAT-26 scores of the MDMA-AT receiving group and the placebo plus therapy group. The MDMA-AT receiving group displayed a remarkable reduction in their EAT-26 scores versus the placebo receiving group, in this instance a reduction in scores is a positive result.

The researchers concluded, “ED is common in individuals with PTSD even in the absence of EDs with active purging and low weight. MDMA-AT significantly reduced ED symptoms compared to therapy with placebo among participants with severe PTSD. MDMA-AT for ED-PTSD appears promising and requires further study.”

 
shutterstock_1571543503-scaled.jpg



Psychedelic Treatment for Eating Disorders*

by Lauren Muhlheim, PsyD, CEDS & Margaret Seide, MD | Very Well Mind | 3 Sep 2021

Unlike most other mental health disorders that can be treated successfully by medication, eating disorders have not been found to be as responsive to traditional psychiatric medicines. Anorexia nervosa has one of the highest mortality rates of any psychiatric illness, and there are few effective psychological treatments and no effective psychiatric medications for the illness.

Even for those disorders such as anxiety and depression for which psychiatric medications exist, the development of new traditional psychopharmacology agents has slowed.

To expand the arsenal of treatments for various psychological disorders, some researchers are now looking at psychedelic medicines as a treatment alternative. And most recently, researchers have begun to examine some of these as potential treatments for eating disorders.

A brief history

The use of hallucinogenic plant medicines in ancient indigenous populations predates written history. Psychedelics were studied as treatments for mental disorders in the 1950s and more than 1000 clinical papers were published in the 1950s and early 1960s.

However, strict laws were passed to prevent their use. The Controlled Substances Act of 1970 placed LSD and other psychedelics known at the time onto Schedule 1, the most restrictive category of drugs. This classification made them virtually impossible to study clinically and effectively ended any significant research into the pharmacology and medical value of psychedelics for more than three decades.

After a lull of several decades, changes in political attitudes and advances in science and technology allowed research to begin again on psychedelics in the 1990s. Most recently, there has been a renewed interest in their use for psychiatric illnesses and studies are once again underway.

How might psychedelics help people with psychiatric disorders?

The exact mechanisms of action of psychedelics are not fully understood, but it is theorized that they significantly reduce activity in the brain’s default mode network (DMN). The DMN are the habitual pathways of communication between brain regions. Just like on a snow-covered hill, we tend to follow the tracks that are already there. Over time, it becomes difficult to take any path other than the ones already established.

The DMN appears to be particularly overactive in certain mental health conditions including depression, anxiety, and OCD. By reducing activity in the DMN, psychedelics may provide a break from deeply ingrained psychological patterns and allow for the setting of new tracks. They may increase brain neuroplasticity and creativity.

How does this apply to eating disorders? Cognitive flexibility is impaired in people with anorexia nervosa, which may stem from an overactive DMN. Hence, researchers hypothesize that psychedelics may be an appropriate treatment method.

How are psychedelics used in psychiatric treatment?

To date, there are only a few systematic studies of treatment models involving psychedelic administration and studies of psychedelic treatment remain in their infancy. What we do seem to know is that psychological support is an important element of treatment with psychedelics. This is referred to as psychedelic-assisted psychotherapy.

The psychological portion of psychedelic medicine usually includes three essential components: preparatory sessions before the drug administration, psychological support during the psychedelic trip, and integration sessions following the dosing session.

It is in these integration sessions that patients solidify insights gained and identify action plans.

Psychedelics are considered relatively safe and, unlike opiates and stimulants, they do not lead to chemical addiction or dependence.

Psychedelic assisted psychotherapy differs from conventional psychiatric treatment in that rather than correcting neurochemical dysfunctions in the brain on a daily basis as most traditional psychiatric medicines do, psychedelic-assisted psychotherapy causes modifications in brain functioning and conscious experience. This in turn can lead to meaningful experiences that create emotional, cognitive, and behavioral changes.

Psychedelics and their potential for treating Eating Disorders

Four particular psychedelics have been the subject of most of the recent psychiatric research and have been or are being investigated in terms of eating disorders—Ketamine, MDMA, Psilocybin, and Ayahuasca.

Ketamine

Ketamine has been used in higher dosages as an anesthetic for decades. In lower dosages, it can temporarily modify consciousness. It has been studied for the treatment of depression, obsessive-compulsive disorder, and post-traumatic stress disorder. Over several decades, research has shown that ketamine has antidepressive properties.

Because it is already an approved medication, it has been incorporated more readily into the treatment of psychiatric disorders via off-label use. Ketamine infusion therapy involves the administration of a single infusion or a series of infusions for the management of psychiatric disorders.

Esketamine nasal spray, a derivative of ketamine, has been separately approved by the FDA for treatment-resistant depression. Trials of ketamine-assisted psychotherapy are also underway and may increase the effectiveness of the treatment. Ketamine may not have been investigated specifically for eating disorders yet, but patients with depression may already be accessing it.

MDMA

MDMA is MethylenodioxyMetamphetamine is commonly confused with the street drug “ecstasy” (also known as “molly”). However, these illegal products are often substitutes that contain no actual MDMA, and may contain only substitutes.

MDMA has been designated a breakthrough therapy for PTSD by FDA, a status that can lead to expedited approval. Therapeutic results with severe treatment-resistant PTSD patients were significant with approximately 70% of participants no longer qualifying for the diagnosis 12 months following treatment.

Currently underway is an open-label, multi-site Phase 2 study of the safety and feasibility of MDMA-assisted psychotherapy for eating disorders. This is a multi-site study of individuals with anorexia nervosa restricting subtype and binge-eating disorder. The study is taking place at three sites including Vancouver, Canada, Toronto, Canada, and Denver, Colorado.

Psilocybin

Psilocybin is the active ingredient in what are commonly known as “magic mushrooms”. Psilocybin has been studied in patients with depression, anxiety, obsessive compulsive disorder, and addiction. Psilocybin received a breakthrough designation from the FDA for individuals with treatment-refractory depression.19 In 2020 Oregon became the first state in the country to legalize psilocybin for medical use.

A current study is underway to explore the safety, tolerability, and efficacy of psilocybin for individuals with anorexia nervosa.

Participants will receive a single 25 mg dose of psilocybin along with psychotherapeutic support, which includes preparation and integration sessions surrounding the experience. This trial is being conducted in Baltimore, Maryland and San Diego, California.

Researcher and psilocybin therapist Stephanie Knatz Peck, Ph.D. who was involved in a psilocybin-assisted trial for the treatment of depression and now is working on the anorexia study said this:

"Psilocybin-assisted therapy holds tremendous promise for mental health. Studies evaluating the therapy for depression, end-of-life anxiety, and smoking cessation have produced impressively robust improvements in symptoms and more studies are underway evaluating the treatment for other mental illnesses."

"We are excited to evaluate the usefulness of this therapy for anorexia nervosa, particularly given the lack of good treatment options currently available. Our UCSD study is a small pilot study evaluating the safety, tolerability, and initial efficacy of psilocybin-assisted therapy for adults with anorexia nervosa."


Ayahuasca

Ayahuasca is a traditional Amazonian psychoactive plant-based tea used in rituals by indigenous leaders and as part of religious ceremonies. Its use has spread to other parts of the world. People who drink ayahuasca usually report powerful visions and mystical experiences. It is usually drunk in traditional-style shamanic, religious ceremonies.

Participants typically drink a small glass of the tea in a ceremony that can last between four to eight hours. They may experience nausea, vomiting, sweating, and altered states of consciousness. Research on ayahuasca shows it might be helpful for mental health problems including depression, anxiety, and addictions.

People with eating disorder histories have been participating in ayahuasca ceremonies. One retrospective study of participants by La France and colleagues concluded that “ceremonial ayahuasca drinking may have promise as an alternative treatment.” The majority of participants surveyed reported significant insights about their illness and believed that ayahuasca has led to reductions in eating disorder symptoms. They also reported that the experience nurtured their self-compassion.

*From the article (including references) here :
 
Last edited:
images


Novel psychedelic compound MEAI a promising treatment for Binge Eating Disorder*

GlobeNewswire | 24 Nov 2021

Clearmind Medicine Inc., a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, has signed an agreement to fund a new research and development project with the Hebrew University of Jerusalem’s Obesity and Metabolism Laboratory, to evaluate the Company’s proprietary compound, MEAI’s direct effect on binge eating including food and water intakes as well as activity and metabolic parameters.

The study, which will be overseen by Prof. Joseph (Yossi) Tam, D.M.D., Ph.D., head of the Obesity and Metabolism Laboratory and Associate Professor of Pharmacology at the Hebrew University’s Institute for Drug Research, will focus on testing the potential of MEAI to treat binge eating and related behaviors, and will support the discovery and development of novel therapeutic strategies to safely treat obesity and its associated metabolic disorders.

Increasingly prevalent in developed nations, the conditions of being overweight and obese are a serious health concern as they contribute to so many other conditions, including heart disease, stroke, type 2 diabetes, fatty liver disease, and certain types of cancers, some of the leading causes of preventable, premature death in the US. The Center for Disease Control and Prevention estimates that about 74% of adults in the US are overweight1 and over 40% are considered obese.

Adi Zuloff-Shani, Ph.D., CEO of Clearmind, commented on the announcement, “The medical community has yet to establish an effective therapeutic or preventative treatment for obesity, despite its increasing prevalence and severe negative impacts on the medical and economic health of people around the world. Clearmind has been able to demonstrate the positive influence MEAI has on binge behavior with regard to alcohol use, and our preliminary research indicates it may have a similar effect on metabolic disorders.”

Prof. Tam added, “I have spent my career exploring the biological mechanisms underlying obesity and the metabolic syndrome, intending to develop an effective drug therapy. After viewing the early data on MEAI, I am optimistic that this compound has the potential to be a building block for a real solution and look forward to working with the Clearmind team to advance our shared objective.”

The first phase of the three-stage study will focus on assessing the direct effect of MEAI on food and water intakes as well as its ability to modulate activity and metabolic parameters.

Following the initial screening, the study will evaluate MEAI’s efficacy as a therapeutic metabolic agent on a high-fat diet-induced obese mouse model, by measuring MEAI’s potential to treat obesity, hepatic injury, glycemic and hormonal imbalance. Lastly MEAI’s binge eating and drinking mitigating properties will be determined by comparison of cumulative food and sucrose preference, respectively.

*From the article here :
 
Last edited:
wol-banner-psychedelics-and-eating-disorders.jpg


Psychedelics and Eating Disorders

by Martha Allitt na Lynn Marie Morski, MD, Esq. | Way of Leaf | 3 Aug 2021

With around 5% of the population affected by eating disorders and with Anorexia Nervosa having the highest mortality rate among all psychiatric illnesses, finding effective treatments is of utmost importance.

Psychedelics have shown promise in treating various mental illnesses. Could they offer a solution to treating eating disorders? We’ve looked at some of the different psychedelic drugs and how they might help in the treatment of eating disorders below.

What are Eating Disorders?

Eating disorders refers to a group of conditions characterized by severe and ongoing disturbed eating. Symptoms of eating disorders include eating too much or too little and having distressing thoughts and feelings relating to food. Eating disorders can be divided into four categories:​
  • Anorexia Nervosa: not eating enough food, overexercising, or doing both​
  • Binge-Eating Disorder: overeating on a regular bases​
  • Bulimia Nervosa: eating large quantities of food and then compensating for the overeating, such as throwing up or taking laxatives​
  • Avoidant/restrictive food intake disorder (ARFID): avoiding certain foods, having restricted food intake or both​
  • Other specified eating or feeding disorder (OSFED): An eating disorder that doesn’t fit in with the expected symptoms of the eating disorders listed above​
More information about each type of eating disorder and where to seek help is listed on the Beat website at the bottom of the page.

Eating disorder prevalence

Statistics estimate that lifetime eating disorders are prevalent in around 8.4% of the female population and 2.2% of the male population. Eating disorders have high rates in adolescence and occur in about 5.8% of the 11-18-year-old population.

Binge-eating disorders are among the most common eating disorder, and anorexia nervosa is among the least common.

Biological mechanisms and current treatments

It’s largely unknown what causes eating disorders, and there is likely a large spectrum of psychological, biological, and environmental factors.

There may be brain changes that play a role in eating disorders. An increase or decrease in neurotransmitters and hormones that influence appetite and mood could lead to issues relating to hunger and thoughts and feelings around food.

Evidence has also suggested that eating disorders may lead to increased activity in parts of the brain associated with control and decreased activity in parts of the brain associated with reward. These brain changes could lead to people being more controlling over their food intake and having reduced pleasure in response to food.

People with eating disorders often have decreased cognitive flexibility – the ability to shift mental and physical behavior. The lack of cognitive flexibility leads to ingrained and restrictive patterns of action and thought around food.
As well as a therapist, eating disorder patients often work with a dietician, who supports them while they work towards a healthy, balanced diet.

Standard eating disorder treatment involves cognitive-behavioral therapy (CBT), which aims to help people change negative thoughts and beliefs. As well as a therapist, eating disorder patients often all work with a dietician, who supports the patient while they work towards a healthy, balanced diet and may help them move towards a healthier weight.

There are no specific medications prescribed to eating disorder patients. However, if an eating disorder accompanies other psychological illnesses like depression or anxiety, patients may receive antidepressant or antianxiety drugs.

How might psychedelics help?

Evidence has shown psychedelic therapy to have promising results in treating various mental illnesses. As eating disorders commonly occur alongside depression and anxiety, psychedelic therapy’s antidepressant and antianxiety effects could help eating disorder patients with depressive and anxious symptoms.

On a biological level, psychedelics can increase cognitive flexibility, meaning they could help patients with eating disorders more easily change their thoughts, feelings, and behaviors towards food. As psychedelics can elicit changes in brain activity, they could also theoretically alter some of the brain-activity changes associated with eating disorders.

Psychedelics and their potential for treating Eating Disorders

Ketamine is a dissociative drug used in anesthesia. In recent years, researchers have increased interest in the use of ketamine in treating various psychological disorders. Much of the scientific interest in using ketamine for mental health treatment has stemmed from evidence showing that intravenous injection can rapidly improve treatment-resistant depression.

A key symptom of eating disorders is compulsive behavior – repeating an action that doesn’t lead to any reward or pleasure, such as throwing up after a meal. One experiment showed that giving patients with eating disorders repeated ketamine infusions over three weeks decreased their compulsive behavior, highlighting how ketamine therapy could be a way to help control this particular symptom.

A case report of a woman who had struggled with anorexia nervosa for over fifteen years showed complete recovery of her disorder through a combined treatment of a ketogenic diet and repeated ketamine infusion therapy.

MDMA for Eating Disorders

MDMA is a drug commonly associated with nightclubs and raving. As well as being a popular recreational stimulant, MDMA therapy has shown to be a powerful treatment in helping patients with post-traumatic stress disorder (PTSD).

Sometimes eating disorders can arise as a coping mechanism to previous traumas. By allowing eating disorder patients better understand and process traumas, MDMA therapy could help patients find trauma coping strategies that don’t involve controlling their diet and weight.

MAPS is planning a phase-two clinical trial for patients with Anorexia Nervosa Restricting-Type and Binge Eating Disorder. It will consist of psychotherapy sessions with and without MDMA. See the link to the trial at the bottom of the article.

Psilocybin Therapy for Eating Disorders

Psilocybin is the active ingredient in magic mushrooms and it leads to classic psychedelic effects, including altered perceptions of time and space and visual hallucinations. It has shown promise in treating various psychological disorders, including depression, anxiety associated with end-of-life, and obsessive-compulsive disorder (OCD).

OCD and eating disorders share several features, including obsessive thoughts and obsessive and compulsive behaviors. The effectiveness of psilocybin therapy in OCD highlights how it could be a worthwhile treatment for eating disorders.

Furthermore, evidence has shown psilocybin can decrease activity in the default-mode network (DMN), a set of connections in the brain that has been linked to rumination. Rumination is the process of being stuck inside a particular thought or set of thoughts and is a common symptom in eating disorders. By decreasing DMN activity, psilocybin could help reduce rumination symptoms in eating disorder patients.

Ayahuasca for Eating Disorders

Ayahuasca is a brew made with the Banisteriopsis cappi vine, which contains monoamine oxidase inhibitors, and the chacruna shrub, which contains the psychedelic compound DMT. Combining these plants causes a prolonged psychedelic experience in which people may have out-of-body experiences and sometimes see otherworldly beings.
More people are traveling to South American countries to take ayahuasca in ceremonies for spiritual, self-growth, and healing purposes.

Ayahuasca has been used throughout history by various communities in South America. It is becoming more popular in the Western world as more people travel to South American countries to take ayahuasca in ceremonies for spiritual, self-growth, and healing purposes.

An interview study investigated the effects of ceremonial ayahuasca in thirteen eating disorder patients. Common outcomes from ayahuasca in the patients included:​
  • Rapid reductions in eating disorder thoughts and symptoms​
  • The root cause of the eating disorder was addressed​
  • Ayahuasca helped patients to process painful feelings and memories​
  • Improved self-love and self-acceptance​

Bottom line on psychedelics for Eating Disorders

Eating disorders refers to a broad spectrum of disordered thoughts and behaviors regarding food and eating which are typically caused by a variable and complex set of psychological and biological factors.

There is evidence to suggest that therapy using different psychedelics could be effective in helping treat people with eating disorders. Although the evidence is limited, the high prevalence and mortality rate of eating disorders mean finding new treatments is crucial and as such it is important this field of research continues.

If you or somebody you’re close to is showing signs of an eating disorder, be sure to visit the Beat website (listed below) for more information on how and where to get support.

Weblinks:

Beat website (eating disorder information and support): https://www.beateatingdisorders.org.uk/
Upcoming MAPS MDMA for eating disorders trial: https://clinicaltrials.gov/ct2/show/NCT04454684

 
Last edited:
file-20211201-25-igjprx.jpg


Can MDMA cure Eating Disorders?*

by James Hallifax | Psychedelic Spotlight | 17 Mar 2022

MAPS has published a study which found that MDMA-assisted therapy significantly reduced symptoms of eating disorders.

Anyone who has ever suffered from an eating disorder, such as anorexia or bulimia, knows that beating the mind virus is a constant struggle. While therapy can help some, for many, the situation can seem hopeless.

But it need not be.

Now, a new tool is coming into focus that may be able to help those engaged in mental civil war: psychedelics. Specifically, evidence is emerging that MDMA, sometimes referred to as ecstasy, when combined with therapy, can effectively treat a range of eating disorders.

The need for an effective treatment is high. Far from being a throwaway joke, as presented in films such as Zoolander, eating disorders like bulimia and anorexia destroy lives. In fact, they are the second deadliest mental illness, after opioid addiction. Tragically, 26% of Americans with eating disorders make an attempt on their own life, and each year 10,200 succeed. That’s one death every 52 minutes. Finally, these disorders are extremely prevalent, with an estimated 9% of the American population expected to battle with one at some point in their life.

Despite the apparent hopelessness, this March, MAPS published a study which found that MDMA-assisted therapy significantly reduced eating disorder symptoms.

The study was part of the nonprofit’s Phase 3 clinical trial attempting to treat PTSD. According to MAPS, PTSD and eating disorders are highly comorbid, meaning that often those who have PTSD also have an eating disorder. Of the 90 PTSD patients in the trial, 46.5% had symptoms of eating disorders either in the clinical or high risk range.

Severity of eating disorder symptoms was measured using a scale called the EATS-26 assessment. Scores can range from 0-78, with a lower score indicating fewer symptoms. Those with a score of 20 or higher most likely have an eating disorder, while scores of 11-19 indicate that a person is at high risk. Of those who received the MDMA treatment, as opposed to the placebo group, there were 12 participants with a score between 11 to 19, and five who had a score of 20 or higher.

Of the five patients who received MDMA that had a diagnosable EATS-26 score, four of the five improved enough to drop their score below the threshold for an eating disorder diagnosis. This compares to the placebo group, where all 6 participants with clinically relevant symptoms remained in a diagnosable category. This shows clearly that the MDMA has a measurable effect on treating eating disorder symptoms, at least in those with more severe symptoms.

In the 12 patients in the MDMA group that had a score of 11-19, after treatment, the number had fallen to six, while of the 12 in the placebo group, after treatment there were still 11 patients with a score of 11 or higher. Again, this shows that MDMA treatment clearly had a positive effect on lessening eating disorder symptoms.

So, does this mean we have found a cure to conditions such as anorexia and bulimia? Well, unfortunately, this evidence is by no means conclusive. First, all patients had PTSD, so if the eating disorders were solely a symptom of PTSD, and the MDMA therapy effectively treated PTSD, then the eating disorder may also disappear. We would need to see data on MDMA treatments for those who only suffer from eating disorders before making more definitive statements.

Second, the sample size was very small, with only 11 patients with diagnosable eating disorders, and 24 who were at risk. Any future studies must have a larger population to ensure that any change is not due to dumb luck. Or, put more scientifically, to ensure that there is statistical significance.

Luckily, we already have several studies planned to dig deeper into this subject. First, MAPS themselves have a Phase 2 study in the works to test treating eating disorders with MDMA. I am very excited to see this data, as it will be our best indication yet of whether MDMA therapy can treat eating disorders. But the psychedelic potential isn’t necessarily limited to MDMA. For example, the company Compass Pathways is set to launch a Phase 2 trial attempting to treat anorexia using psilocybin.

Though we of course need more data, it makes sense that MDMA therapy may be able to treat eating disorders. It has been hypothesized that eating disorders often are rooted in deep seated trauma. For example, a perceived failure to live up to particular beauty standards as a child, causing internal shame and self loathing that persists into adulthood.

The reason MDMA and other psychedelics have been successful in treating mental conditions such as PTSD, depression, and addiction, is that these substances allow you to face your trauma head-on, to come to terms with it and ultimately accept it. In this context, expanding psychedelic therapy to treat eating disorders makes sense.

Though we are still early, this data is very promising. Perhaps in the future, we will be able to say that MDMA therapy is an effective treatment for eating disorders.

To learn more about the MAPS Phase 3 trial, where MDMA therapy effectively CURED 67% of severe PTSD sufferers, read this story.

*From the article here :
 
eneating-disorders-and-pregnancyesel-embarazo-y-trastornos-de-la-alimentacion.jpg



Psychedelics and Eating Disorders*

by Adele Lafrance, PhD & Reid Robison, MD | Eating Disorders | 23 Jan 2021

Clinicians working with eating disorders are well aware that these conditions can be the most difficult to treat. The stakes are high, as millions of individuals are affected, they have a significant impact on quality of life, and they can be lethal in some cases. While there are a variety of promising treatment options, despite everyone’s best efforts—clinicians, clients, and families alike—too many individuals continue to suffer, even after several courses of treatment. Pharmacotherapy options for eating disorders are also lacking—anorexia nervosa has no Food and Drug Administration–approved medications, and bulimia nervosa and binge eating disorder each have only one recognized option (fluoxetine and lisdexamfetamine, respectively). In severe and enduring cases of eating disorders, palliative care approaches are even considered. There exists an urgency to continue to develop treatment modalities to help address these unmet needs.

There has been a remarkable resurgence of research in the past two decades that supports the therapeutic use of psychedelic medicines in the treatment of emotion-based disorders including post-traumatic stress disorder (PTSD), major depressive disorder, and addictions, to name a few. Psychedelic-assisted psychotherapy is emerging as a promising new treatment paradigm, in which the use of psychedelics, paired with psychotherapy, has the potential to yield significant breakthroughs for individuals with difficult-to-treat mental health conditions, including eating disorders. A number of psychedelic clinical research studies for eating disorders are in preparation or have begun, including emotion-focused ketamine-assisted psychotherapy (EF-KAP) for anorexia nervosa (Cedar Psychiatry by Novamind), psilocybin-assisted psychotherapy for anorexia nervosa (Johns Hopkins University; Imperial College London; University of California, San Diego), and MDMA-assisted psychotherapy for anorexia nervosa and for binge eating disorder (MAPS).

How might psychedelics help with Eating Disorders?

Though theoretical mechanisms of action of psychedelic medicines are still being investigated, a growing body of research points toward the following ways psychedelics might help individuals with eating disorders in particular: 1) the potential to alleviate symptoms that relate to serotonergic signaling and cognitive inflexibility, and 2) the induction of desirable brain states that might accelerate therapeutic processes.

Classic psychedelics—like psilocybin, LSD, and ayahuasca—are thought to interrupt what is called the default mode network (DMN), which is often considered the neurobiological seat of the “ego” in the brain. The DMN is a collection of pathways that govern our self-image, our autobiographical memories, and our deeply ingrained beliefs and thought patterns. While results from brain imaging studies in eating disorders are diverse, findings seem to converge on a common theme of overactivity in the DMN, showing up in our clients as rumination over caloric intake and food rules, compulsive exercise or eating behavior patterns, body checking, etc. And, like a ski slope, the mind develops and strengthens pathways as we repeat patterns. Every time the thoughts and actions are engaged, the grooves get deeper and deeper, and before long, no matter where we start, we’re likely to slip into the same ruts and end up following the same path down the mountain. When a psychedelic medicine is ingested, the DMN is downregulated, and it’s like the mind benefits from a fresh coat of powder. This fresh coat of powder provides a blank slate—offering a welcome break from the eating disorder patterns, allowing for increased connectivity between other neuronal networks, and creating the potential to move beyond self-imposed limitations that can be so debilitating in those affected. In other words, the individual has the opportunity to travel down a new set of tracks, allowing them to consciously chart a course that isn’t governed entirely by eating disorder thoughts and urges.

The second theorized mechanism in support of psychedelics as a treatment tool for eating disorders involves the way in which psychedelics can help foster desirable brain states that might accelerate therapeutic processes. Specifically, the increased neuroplasticity observed with classic psychedelics and ketamine can also be leveraged in the context of psychotherapy. For example, when we use ketamine as a treatment for eating disorders, we schedule psychotherapy sessions within the 24- to 48-hour window of potential for neurogenesis to optimize outcomes. Also facilitative in the therapy setting, MDMA, while not a classic psychedelic, is unique among consciousness-altering substances in its ability to promote acceptance of and empathy for self and others. In addition to elevating oxytocin levels, MDMA stimulates the release of the monoamines serotonin, norepinephrine, and dopamine, resulting in an improved mood and increased sociability. Brain imaging after being administered MDMA shows decreased amygdala activation, and the reduced fear response that follows allows the client to emotionally engage in therapy without becoming overwhelmed by anxiety or negative affective states. As of September 2020, the Multidisciplinary Association for Psychedelic Studies is conducting phase 3 trials of MDMA-assisted psychotherapy for treatment-resistant PTSD, under the FDA’s breakthrough therapy designation, and the results are quite striking. An analysis of phase 2 data showed that at 12-month follow-up, 67 percent of participants no longer met criteria for PTSD.

“I’m tempted to say MDMA gave me ‘hope,’ but that word isn’t right—the insight was more substantive than hope. I’d held the sensation in my body; I understood, at a visceral level, what might someday be mine: the sense of peace and joy within my body. For me, the therapeutic process could unfurl from there.” —MDMA participant

We’ve also been analyzing data gathered from interviews of individuals with eating disorders who participated in ceremonial ayahuasca use. When asked to describe the positive effects of this traditional Amazonian tea, similar themes emerged in that individuals shared that participation led to an ability to face and work through challenging emotions and memories. They also reported decreases in symptoms of anxiety and depression, including urges to self-harm and suicidal ideation.

“I still experience periods of feeling anxiety, but I feel like they don’t last as long, whereas before, I would spiral downward and get depressed and then start to restrict and start to purge and binge and all of that. I feel like I can notice when my energy is changing, and then I am more able to be with it and sort of resist it, and then it moves after.” —Ayahuasca participant

Several respondents also shared that they benefited from increased capacities for mindfulness, improved body image, and strengthened relationships with important others, including a new or deeper connection with nature and/or God or Spirit. Participants even described an “embodied knowing” of self-love, where they were able to recognize from a deeper place that: “I am worthy. I am beautiful as I am inside and out”—a powerful antidote to the harsh inner critic so common in eating disorders.

“I seem to think about myself and talk about myself a lot more kindly than I previously did. And I’m a lot gentler [to myself].” —Ayahuasca participant

Family-based psychedelic medicine for Eating Disorders

One of the unique facets of treatment in the field of eating disorders is the recognition of the importance of caregiver involvement. Thanks to several different lines of research, and the tireless efforts of parent advocacy groups, contemporary approaches to eating disorder treatment have evolved to include families as active supports in the recovery process. Recent research outcomes have confirmed the benefits of carer involvement, including improved outcomes for both the sufferer and their family members, and it is our goal to continue this important work in the context of psychedelic psychotherapies for eating disorders.

To do so, we propose three models of family-based psychedelic medicine. The first model involves the recruitment of caregivers who learn specific skills to support their loved one throughout the course of psychedelic-assisted psychotherapy, creating an optimal home environment for healing and growth, and reducing the likelihood of problematic interactional patterns that could inadvertently maintain symptoms. For example, in the context of our study examining the safety, feasibility, and preliminary outcomes of EF-KAP, an identified caregiver (partner or parent) attends the preparation session with their loved one to learn about the model, and offers support during the medicine sessions. They also learn skills to assist their loved one with emotion processing throughout the treatment protocol and beyond. We are using a similar protocol in the context of MDMA-assisted psychotherapy for eating disorders, in which caregivers will learn emotion coaching skills and participate in preparation and integration sessions to create a bridge from the therapy session to life at home.

“It’s been really great to have him [spouse] involved. He’s using the techniques he learned, and it feels really good.” —EF-KAP participant

The second model involves the recruitment of caregivers who participate in medicine sessions alongside their loved one, thereby leveraging the neurobiological bond in order to deepen the process of healing and growth, including attending to problematic relational patterns and old injuries, if relevant. In fact, it is our hope that in the not-so-distant future, we can develop and research a treatment protocol where the family of an adult who is struggling with an eating disorder can participate in psychedelics-assisted family therapy to support the recovery process. Our colleagues who have had the opportunity to facilitate this type of treatment prior to the classification of MDMA as a Schedule I Controlled Substance have shared with us incredible stories of hope and healing. It also creates opportunities for systemic healing, including the transformation of intergenerational cycles of pain.

The third model involves caregivers who participate in psychedelic-assisted psychotherapy on behalf of their loved one, who, for medical or psychiatric reasons, cannot participate themselves. We’ve known of a woman (Anne) whose daughter (Heather) suffered from what would be considered a treatment-resistant eating disorder. They had participated in several specialized eating disorder treatment programs, at various levels of care, but with little improvement and growing despair. Anne thought that perhaps the plant medicine ayahuasca could help Heather get a break from the eating disorder—at least temporarily—and maybe even offer new hope for eventual recovery. Unfortunately, however, Heather was ineligible to attend the out-of-country retreat due to medical instability. Her mother made the decision to attend on her daughter’s behalf, as a surrogate healer. She shared that it was an incredibly powerful experience—that the ayahuasca ceremonies helped her to understand her daughter’s suffering in a new way, including what Heather needed from her to face her fears around food and weight. She went home with a new perspective and far more energy to keep up the fight for recovery, as the retreat also afforded her a much-needed opportunity to rest and recharge.

Conclusion

We’ve witnessed time and time again the extent to which the field is made up of caring, compassionate, and hardworking clinicians working hard on behalf of those suffering and their families. And one thing we can all agree on is that despite our best efforts, there remains a need for innovative treatment strategies to serve those for whom conventional treatments have been insufficient, ineffective, or even harmful. Although much more research is needed to better understand the safety and efficacy of psychedelic medicines in eating disorders, we feel it is a very worthwhile pursuit. One thing is clear to us, however, and that is the importance of coordinating these efforts with conventional treatment approaches. By doing so, we can build on the decades of research and clinical practice that have shaped treatment delivery across the spectrum of eating disorders, including psychedelic psychotherapy as another treatment ingredient for those for whom it might be appropriate. We have tremendous hope that psychedelic medicine can alleviate suffering for many along the continuum of recovery, as well as for their families, and we look forward to sharing the results of our studies as they become available.

*From the article (including references) here :
 
Last edited:
Top